package org.qsari.effectopedia.data.generated;
import org.qsari.effectopedia.base.ids.ReferenceIDW;
import org.qsari.effectopedia.core.object.elemets.EssetialityDescription;
import org.qsari.effectopedia.core.objects.DescriptionSection;
import org.qsari.effectopedia.core.objects.DescriptionSection.ContentFormat;
import org.qsari.effectopedia.core.objects.DescriptionSection_Structured;
import org.qsari.effectopedia.core.objects.Effect_AdverseOutcome;
import org.qsari.effectopedia.core.objects.Effect_DownstreamEffect;
import org.qsari.effectopedia.core.objects.Effect_MolecularInitiatingEvent;
import org.qsari.effectopedia.core.objects.Initiator_ChemicalStructure;
import org.qsari.effectopedia.core.objects.Link.LinkType;
import org.qsari.effectopedia.core.objects.Link_ChemStructToMIE;
import org.qsari.effectopedia.core.objects.Link_EffectToEffect;
import org.qsari.effectopedia.core.objects.Reference;
import org.qsari.effectopedia.core.objects.TestResponseMapping;
import org.qsari.effectopedia.core.objects.Test_ExVivo;
import org.qsari.effectopedia.core.objects.Test_InChemico;
import org.qsari.effectopedia.core.objects.Test_InVitro;
import org.qsari.effectopedia.core.objects.Test_InVivo;
import org.qsari.effectopedia.data.DataSource;
import org.qsari.effectopedia.data.RevisionBasedDS;
import org.qsari.effectopedia.defaults.DefaultEffectopediaObjects;

public class ss_aop	extends SourceGeneratedPathway {

public ss_aop(DataSource dataSource) {
super("Covalent Protein binding leading to Skin Sensitisation ","",dataSource,"D://Java//org.qsari.effectopedia//test//OECD//Covalent Protein binding leading to Skin Sensitisation ");
}
protected Initiator_ChemicalStructure initiator_chemicalstructure1;
protected Link_ChemStructToMIE link_chemstructtomie2;
protected Effect_MolecularInitiatingEvent effect_molecularinitiatingevent3;
protected Link_EffectToEffect link_effecttoeffect4;
protected Link_EffectToEffect link_effecttoeffect5;
protected Effect_DownstreamEffect effect_downstreameffect6;
protected Effect_DownstreamEffect effect_downstreameffect7;
protected Link_EffectToEffect link_effecttoeffect8;
protected Link_EffectToEffect link_effecttoeffect9;
protected Effect_DownstreamEffect effect_downstreameffect10;
protected Link_EffectToEffect link_effecttoeffect11;
protected Effect_AdverseOutcome effect_adverseoutcome12;
protected TestResponseMapping testresponsemapping13;
protected Test_InChemico test_inchemico14;
protected TestResponseMapping testresponsemapping15;
protected TestResponseMapping testresponsemapping16;
protected TestResponseMapping testresponsemapping17;
protected Test_InVitro test_invitro18;
protected Test_InVitro test_invitro19;
protected Test_InVitro test_invitro20;
protected Test_ExVivo test_exvivo21;
protected TestResponseMapping testresponsemapping22;
protected Test_InChemico test_inchemico23;
protected Test_InChemico test_inchemico26;
protected TestResponseMapping testresponsemapping27;
protected Test_InChemico test_inchemico28;
protected TestResponseMapping testresponsemapping29;
protected Test_InChemico test_inchemico30;
protected TestResponseMapping testresponsemapping31;
protected Test_InChemico test_inchemico32;
protected TestResponseMapping testresponsemapping33;
protected Test_InChemico test_inchemico34;
protected TestResponseMapping testresponsemapping35;
protected Test_InVivo test_invivo36;
protected TestResponseMapping testresponsemapping37;
protected Test_InVivo test_invivo38;
protected TestResponseMapping testresponsemapping39;
protected Test_InVivo test_invivo40;
protected TestResponseMapping testresponsemapping41;
protected Test_InVivo test_invivo42;
@Override
public void generateContent()
{genreateRevision1();
storeRevision();
((RevisionBasedDS) dataSource).setLocation(pathway);
}
public void genreateRevision1() {

initiator_chemicalstructure1 = new Initiator_ChemicalStructure(pathway, dataSource);
initiator_chemicalstructure1.setTitle("1-CHLORO-2,4- DINITROBENZENE   ");
initiator_chemicalstructure1.getStructure2DImage().setValue("https://apps.ideaconsult.net/ambit2/depict/cdk?search=C1%3DCC%28%3DC%28C%3DC1%5BN%2B%5D%28%3DO%29%5BO-%5D%29%5BN%2B%5D%28%3DO%29%5BO-%5D%29Cl&w=200&h=200&media=image/png");
initiator_chemicalstructure1.getIdentification().setPropertyValue(0,"97007");
initiator_chemicalstructure1.getIdentification().setPropertyValue(1,"n/a");
initiator_chemicalstructure1.getIdentification().setPropertyValue(2,"C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Cl");
initiator_chemicalstructure1.getIdentification().setPropertyValue(3," ");
initiator_chemicalstructure1.getIdentification().setPropertyValue(4," ");
initiator_chemicalstructure1.getIdentification().setPropertyValue(5," ");
initiator_chemicalstructure1.getIdentification().setPropertyValue(6,"");
initiator_chemicalstructure1.setSynonymsList(new String[] {" "});

effect_molecularinitiatingevent3 = new Effect_MolecularInitiatingEvent(pathway, dataSource);
effect_molecularinitiatingevent3.setTitle("Protein, Covalent Binding");
effect_molecularinitiatingevent3.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "molecular");
effect_molecularinitiatingevent3.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LIFE_STAGE.DIMENSION_INDEX, "adult");
effect_molecularinitiatingevent3.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
effect_molecularinitiatingevent3.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_TIME_TO_EFFECT.DIMENSION_INDEX, "0.0");
effect_molecularinitiatingevent3.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_EFFECT_TERM.DIMENSION_INDEX, "unknown");
effect_molecularinitiatingevent3.getDescriptionIDs().set(new DescriptionSection(effect_molecularinitiatingevent3,dataSource,"Definition","The molecular initiating event is covalent binding of electrophilic chemical species with selected nucleophilic molecular sites of action in proteins generating immunogenic neoantigens through a process termed haptenisation[1];[2]. In contrast to receptor-mediated chemical interactions electrophiles are not specific with regard to their molecular target. Moreover, some chemicals are able to react with several different nucleophilic chemical substituents. Therefore, the identification of the specific target protein is not considered to be critical. Moreover, it is recognized that reactivity measured with a particular nucleophilic target or model nucleophile does not necessarily reflect a specific chemical reaction, as many reactions target the same chemical substituent[3]. For toxicological endpoints for which protein binding is important, the biological nucleophile is assumed to be selected amino acids. The exact extent of adduct formation to each amino acid is dependent on the relative hardness / softness of the electrophile and nucleophile[3]. The inability to identify the exact biological nucleophile is deemed less important than information regarding the electrophile. As noted in the hard-soft acid base theory, a soft electrophile will have a relative preference for a soft nucleophile; while a hard electrophile will have a relative preference for a hard nucleophile. As a consequence, for a series of electrophiles assigned to the same mechanistic cluster within a particular domain, the relative rates of reactivity between each electrophile and any nucleophile will remain the same. In other words, while absolute reactivity may vary with protocols, relative reactivity will usually not vary significantly[3]. Binding experiments with small model nucleophiles reveal that, within a particular reaction within a mechanism, the rate of reactivity varies markedly. Moreover, while some compounds appear to bind exclusively with thiol or amine, others bind to a variety of nucleophiles. However, an electrophile is most likely to exhibit a preference for a particular nucleophile. In more complex systems, nucleophilic target preferences may be masked by other factors. It is self-evident that the number of cysteine and lysine residues within a protein will impact target probability. For example, for serum albumin, a major serum protein, 10% of the amino acid residues are lysine but albumin has very few free cysteine residues. Also, it is self-evident that a target site (e.g. cysteine or lysine) which is located on an exposed surface of a protein is more likely to react with an electrophile than one that is located within a grove or fold of a protein. Such steric constraints are imposed by the primary structure (i.e. amino acid sequence) of the peptide or protein, as well as the secondary and tertiary structure of proteins imposed by disulfide bridges, and folding and coiling. Similarly, the microenvironment of the reaction site (e.g. hydrophilic versus hydrophobic) may affect the probability of a particular reaction. Free cysteine residues are more abundant in proteins in the aqueous cytosol than in the non- aqueous biomembranes [4]. An ancillary event in identifying protein-binding is metabolism and/or abiotic transformation (e.g. autoxidation)[5]. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
effect_molecularinitiatingevent3.getDescriptionIDs().set(new DescriptionSection(effect_molecularinitiatingevent3,dataSource,"Measurment/detection","In silico Methods \n\nIt is generally recognized that reaction-based methods, as opposed to other means of defining chemical similarity, allow for easier interpretation and provide greater confidence in their use[6]. Chemical reactions related to covalent protein binding have recently been reviewed[7];[8];[9]. Measurements and estimations of reactivity have also recently been reviewed[1];[3]. Computational or in silico techniques to predict chemical reactivity have been developed; they vary in complexity from the relatively simple approach of forming chemical categories from 2D structural alerts (i.e. SARs for qualitative identification of chemical sub-structures with the potential of being reactive), such as used in the Organisation for Economic Co-Operation and Development (OECD)QSAR Toolbox[10] to QSAR models (i.e. quantitative prediction of relative reactivity) as described by Schwöbel et al.[11]. \n\nIn Chemico Protocols and Databases \n\nWhile methionine, histidine, and serine all possess nucleophilic groups that are found in skin proteins, the –SH group of cysteine and the ε-NH2 group of lysine are the most often studied. Soft electrophilic interactions involving the thiol group can be modelled with small molecules. Glutathione (GSH; L-γ-glutamyl-L-cysteinyl-glycine) is the most widely used model nucleophile in soft electrophilic reactivity assays. Typically, chemicals are incubated with GHS and, after a defined reaction time, the concentration of free thiol groups is measured. Such depletion based assays assume adduct formation, which is typically not confirmed. Good relationships between GSH reactivity and toxicity have been demonstrated. Examples of this method can be found in the literature[3];[12];[13];[14]. Recently, OECD adopted the new Test Guideline (TG) No442C: In chemico skin sensitisation – Direct Peptide Reactivity Assay (DPRA). This method quantifies the reactivity of chemicals towards model synthetic peptides containing either lysine or cysteine[15]. The DPRA protocol can be found in the EURL ECVAM Database Service on Alternative Methods to animal experimentation (DB-ALM): Protocol No154 for Direct Peptide Reactivity Assay (DPRA) for skin sensitisation testing[16]. The importance of reaction chemistry for sensitisation indicates that identification of the reaction limited chemical spaces is critical for using the proposed AOP. Systematic databases for reaction-specific chemical spaces are being developed. For example, in chemico databases reporting measurements of reactive potency currently exist for Michael acceptors ([14];[17];[18]). The use of model nucleophiles containing primary amino (–NH2) groups, such as in the amino acids lysine are less well-documented, with the principle of measuring relative reactivity being the same as for thiol[1]. \n\n<h3><span id=\"Overview_table:_How_it_is_measured_or_detected\" class=\"mw-headline\">Overview table: How it is measured or detected</span></h3>\n\n<table id=\"Event396\" class=\"wikitable\">\n\n<tbody>\n\n<tr><th>Method(s)</th><th>Reference</th><th>URL</th><th>Regulatory\n\n<p>Acceptance</p>\n\n</th><th>Validated</th><th>Non\n\n<p>Validated</p>\n\n</th></tr>\n\n<tr>\n\n<td rowspan=\"2\">Direct Peptide Reactivity Assay (DPRA)</td>\n\n<td>TG 442C</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.oecd-ilibrary.org/environment/test-no-442c-in-chemico-skin-sensitisation_9789264229709-en\" target=\"_blank\" rel=\"nofollow\">[1]</a></td>\n\n<td rowspan=\"2\">X</td>\n\n<td rowspan=\"2\">X</td>\n\n<td rowspan=\"2\">&nbsp;</td>\n\n</tr>\n\n<tr>\n\n<td>DB-ALM</td>\n\n<td><a class=\"external autonumber\" href=\"http://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index?id_met=1953\" target=\"_blank\" rel=\"nofollow\">[2]</a></td>\n\n</tr>\n\n</tbody>\n\n</table>\n\n").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 1);
effect_molecularinitiatingevent3.getDescriptionIDs().set(new DescriptionSection(effect_molecularinitiatingevent3,dataSource," Taxonomic Applicability"," <h3>&nbsp;</h3>\n\n<table id=\"Specproof\" class=\"wikitable sortable jquery-tablesorter\">\n\n<thead>\n\n<tr><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Scientific Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Evidence</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Links</th></tr>\n\n</thead>\n\n<tbody>\n\n<tr>\n\n<td>human</td>\n\n<td>Homo sapiens</td>\n\n<td>&nbsp;</td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n<tr>\n\n<td>guinea pig</td>\n\n<td>Cavia porcellus</td>\n\n<td>&nbsp;</td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10141\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n<tr>\n\n<td>mouse</td>\n\n<td>Mus musculus domesticus</td>\n\n<td>&nbsp;</td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10092\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n</tbody>\n\n</table>").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 2);
effect_molecularinitiatingevent3.getDescriptionIDs().set(new DescriptionSection(effect_molecularinitiatingevent3,dataSource," Evidence for Chemical Initiation of this Molecular Initiating Event"," The in chemico, in vitro, and in vivo experimental evidence is logical and consistent with the mechanistic plausibility proposed by covalent reactions based on the protein binding theory ([1];[19];[20]). In selected cases, (e.g. 1-chloro-2,4-dinitrobenzene) where the same compound has been examined in a variety of assays (see Annex 1 of[21]), the coherence and consistency of the experimental data is excellent. Alternative mechanism that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP. While covalent reactions with thiol groups and to lesser extent amino groups, are clearly supported by the proposed AOP, reactions targeting other nucleophiles may or may not be supported by the proposed AOP. Limited data on chemical reactivity shows that two competing reactions are possible, the faster reaction dominates. However, this has yet to be proven in vitro or in vivo. \n\nEarlier work on the molecular basis of skin sensitisation was reviewed by Lepoittevin et al. (1998)[22], since then our knowledge of skin sensitisation has continued to expand. Recent reviews (see[3];[9];[20];[22];[23];[24];[25]) repeatedly stress the same key steps leading to sensitisation. These events include hapten formation (i.e., the ability of a chemical to react with skin proteins). ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 3);
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"1. Gerberick F, Aleksic M, Basketter D, Casati S, Karlberg AT, Kern P, Kimber I, Lepoittevin JP, Natsch A, Ovigne JM, Rovida C, Sakaguchi H and Schultz T. 2008. Chemical reactivity measurement and the predictive identification of skin sensitisers. Altern. Lab. Anim. 36: 215-242. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"2. Karlberg AT, Bergström MA, Börje A, Luthman K and Nilsson JL. 2008. Allergic contact dermatitis- formation, structural requirements, and reactivity of skin sensitizers. Chem. Res. Toxicol. 21: 53-69. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"3. Schwöbel JAH, Koleva YK, Bajot F, Enoch SJ, Hewitt M, Madden JC, Roberts DW, Schultz TW and Cronin MTD. 2011. Measurement and estimation of electrophilic reactivity for predictive toxicology. Chem. Rev. 111: 2562-2596. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"4. Hopkins JE, Naisbitt DJ, Kitteringham NR, Dearman RJ, Kimber I and Park BK. 2005. Selective haptenation of cellular or extracellular proteins by chemical allergens: Association with cytokine polarization. Chem. Res. Toxicol. 18: 375-381. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"5. OECD 2010. Test No.442B: Skin sensitization: Local Lymph Node Assay: BrdU-ELISA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090996-en. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"6.Freidig AP and Hermens JLM. 2001. Narcosis and chemical reactivity QSARs for acute toxicity. Quant. Struct. Act. Rel. 19: 547-553. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"7. Roberts DW, Aptula AO, Patlewicz G, Pease C. 2008. Chemical reactivity indices and mechanism-based read-across for non-animal based assessment of skin sensitisation potential. J.Appl. Toxicol. 28: 443-454. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"8. Enoch SJ, Ellison CM, Schultz TW, Cronin MTD. 2011. A review of the electrophilic reaction chemistry involved on covalent protein binding relevant to toxicity. Crit. Rev. Toxicol. 41: 783– 802. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"9.  OECD 2011. Report of the Expert Consultation on Scientific and Regulatory Evaluation of Organic Chemistry-based Structural Alerts for the Identification of Protein-binding Chemicals. OECD Environment, Health and Safety Publications Series on Testing and Assessment No. 139. ENV/JM/MONO(2011). ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"10. Basketter DA, Pease C, Kasting G, Kimber I, Casati S, Cronin MTD, Diembeck W, Gerberick F, Hadgraft J, Hartung J, Marty JP, Nikolaidis E, Patlewicz G, Roberts DW, Roggen E, Rovida C, van de Sandt J. 2007. Skin sensitisation and epidermal disposition: The relevance of epidermal disposition for sensitisation hazard identification and risk assessment. The report of ECVAM workshop 59. Altern. Lab. Anim. 35: 137-154. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"11. Schwöbel J, Wondrousch D, Koleva YK, Madden JC, Cronin MTD, Schüürmann G. 2010. Prediction of Michael type acceptor reactivity toward glutathione. Chem. Res. Toxicol. 23: 1576-1585. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"12.  Kato H, Okamoto M, Yamashita K, Nakamura Y, Fukumori Y, Nakai K, Kaneko H. 2003. Peptide-binding assessment using mass spectrometry as a new screening method for skin sensitization. J. Toxicol. Sci. 28: 19-24. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"13. dos Santos GG, Reinders J, Ouwhand K, Rustemeyer T, Scheper RJ, Gibbs S. 2009. Progress on the development of human in vitro dendritic cell based assays for assessment of skin sensitizing potential of compounds. Toxicol. Appl. Pharmacol. 236: 372-382. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"14. Böhme A, Thaens D, Paschke A, Schüürmann G. 2009. Kinetic glutathione chemoassay to quantify thiol reactivity of organic electrophiles – Application to α, β-unsaturated ketones, acrylates, and propiolates, Chem. Res. Toxicol. 22: 742-750. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"15. OECD. Test No 442C: In chemico skin sensitisation: Direct Peptide Reactivity Assay (DPRA). 2015. OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing. Doi 10.1787/9789264229709-en. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"16. EURL ECVAM DB-ALM. Protocol No154: Direct Peptide Reactivity Assay for skin sensitisation testing. Available on: http://ecvam-dbalm.jrc.ec.europa.eu/. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"17. Yarbrough JW and Schultz TW. 2007. Abiotic sulfhydryl reactivity: A predictor of aquatic toxicity for carbonyl-containing α,β-unsaturated compounds. Chem. Res. Toxicol. 20: 558-562. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"18. Roberts DW and Natsch A. 2009. High throughput kinetic profiling approach for covalent binding to peptides: Application to skin sensitisation potency of Michael acceptor electrophiles. Chem. Res. Toxicol. 22: 592-603. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"19.Karlberg AT, Bergström MA, Börje A, Luthman K, Nilsson JL. 2008. Allergic contact dermatitisformation, structural requirements, and reactivity of skin sensitizers. Chem. Res. Toxicol. 21: 53-69. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"20. Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau A, Aptula A, Bal-Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Leite SB, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tähti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM.2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch Toxicol.85(5):367-485. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"21. OECD. 2012. The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins. Part 1: Scientific Evidence. Series on Testing and Assessment No. 168. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"22. Lepoittevin JP, Basketter DA, Goossens A and Karlberg AT (eds) 1998. Allergic contact dermatitis: the molecular basis. Springer, Berlin. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"23. Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. 2009. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64: 1699-1714. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"24. Aeby P, Ashikaga T, Bessou-Touya S, Schapky A, Geberick F, Kern P, Marrec-Fairley M, Maxwell G, Ovigne JM, Sakaguchi H, Reisinger K, Tailhardat M, Martinozzi-Teisser S and Winkler P. 2010. Identifying and characterizing chemical skin sensitizers without animal testing; Colipa’s research and methods development program. Toxicol. In Vitro 24: 1465-1473. ").<Reference> makeItLive());
effect_molecularinitiatingevent3.getReferenceIDs().add(new Reference(effect_molecularinitiatingevent3,dataSource,"25. Basketter DA and Kimber I. 2010. Contact hypersensitivity. In: McQueen, C.A. (ed) Comparative Toxicology Vol. 5, 2nd Ed. Elsevier, Kidlington, UK, pp. 397-411. ").<Reference> makeItLive());

effect_downstreameffect6 = new Effect_DownstreamEffect(pathway, dataSource);
effect_downstreameffect6.setTitle("Keratinocytes, Activation");
effect_downstreameffect6.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
effect_downstreameffect6.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
effect_downstreameffect6.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect6,dataSource,"Definition","Keratinocytes are the major cell type of the epidermis of the skin. They are known to be the primary site of skin metabolism and play an important role in epithelial Dendritic Cells (DC) activation. Uptake of the hapten-protein complex formed during covalent binding by keratinocytes activates multiple events, including the release of pro-inflammatory cytokines (i.e. IL-18) and the induction of cyto-protective cellular pathways. Hapten-protein complexes can activate the inflammasome ([1];[2]) and in so doing induce IL-18 production. Activation of the pro-inflammatory cytokine IL-18 results from cleavage of inactive IL-18 precursor protein by inflammasome-associated caspase-1[3]. Intracellular Nod-like receptors (NLR) contain sensors for a number of cellular insults. Upon activation, NLRs oligomerise form molecular complexes (i.e. inflammasomes) that are involved in the activation of inflammatory-associated caspases, including caspase-1. Induction of intracellular levels of IL-18 exhibit responses upon exposure to hapten-protein complexes which can be used to establish potency[4]. Keratinocyte exposure to allergens also results in induction of antioxidant/electrophile response element ARE/EpRE-dependent pathways[5]. Briefly, reactive chemicals bind to Keap1 (Kelch-like ECH-associates protein 1) that normally inhibit the nuclear erythroid 2-related factor 2 (Nrf2). Released Nrf2 interacts with other nuclear proteins and binds to and activates ARE/EpREdependent pathways, including the cytoprotective genes NADPH-quinone oxidoreductase 1 (NQO1) and glutathione S-transferase (GSHST), among others ([5];[6]). \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
effect_downstreameffect6.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect6,dataSource,"Measurment/detection","Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible?  \n\nInvestigations have focused on the DNA antioxidant-response elements (ARE), also known as electrophile response element. OECD TG 442D is the validated test guideline for measuring the activation of the antioxidant/electrophile response element (ARE) - dependant pathway[7]). Currently, the only in vitro ARE-Nrf2 luciferase test method covered by this Test Guideline is the KeratinoSensTM. This assay uses a luciferase reporter gene under control of a single copy of the ARE element of the human AKR1C2 gene stably inserted into immortalized human keratinocytes (HaCaT cells)[8]. The KeratinoSensTM protocol can be found in the EURL ECVAM Database Service on Alternative Methods to animal experimentation (DB-ALM): Protocol No155 for KeratinoSensTM[9]. The Keap1/Nrf2/ARE/EpRE cell signalling assay is also the mechanistic basis for the work on skin sensitisation chemicals at CeeTox Inc.[10]. This work includes quantitative realtime polymerase chain reaction measurements of the relative abundance of mRNA for eleven selected genes whose expression is controlled by one of the three following pathways: Keap1/Nrf 2/ARE/EpRE, ARNT/AhR/XRE, and Nrf1/MTF/MRE. Interestingly, both Emter et al.[8] and McKim et al.[10] combine their cell signalling results with chemical reactivity data in algorithms, which can be viewed as a first step in using the AOP in quantitative assessment. \n\nIn vitro assays based on IL-18 induction in human keratinocytes (cell line NCTC 2544)[11] or IL-8 induction in THP-1 cells[12] have also been developed to identify allergens. Other studies have described chemokines (e.g. CCL2, CCL4) and receptor (e.g. CCR7) (see[13]). \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 1);
effect_downstreameffect6.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect6,dataSource," Evidence Supporting Taxonomic Applicability"," <h3><span id=\"Taxonomic_Applicability\" class=\"mw-headline\">Taxonomic Applicability</span></h3>\n\n<table id=\"Specproof\" class=\"wikitable sortable jquery-tablesorter\">\n\n<thead>\n\n<tr><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Scientific Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Evidence</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Links</th></tr>\n\n</thead>\n\n<tbody>\n\n<tr>\n\n<td>human</td>\n\n<td>Homo sapiens</td>\n\n<td><a title=\"Event:826\" href=\"https://aopwiki.org/wiki/index.php/Event:826#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n<tr>\n\n<td>mouse</td>\n\n<td>Mus musculus</td>\n\n<td><a title=\"Event:826\" href=\"https://aopwiki.org/wiki/index.php/Event:826#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n</tbody>\n\n</table>\n\nA dose-dependent release of IL-18 has been shown following exposure of the murine keratinocyte cell line HEL-30 to sensitisers[4]. Moreover, a concentration-dependant increase in intracellular IL-18 at non-cytotoxic concentrations of chemicals was observed in the human keratinocyte cell line NCTC2455 following 24-h treatment[11]. ").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 2);
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"1. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galán JE, Askenase PW, Flavell RA. 2006. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24: 317-327. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"2.Watanabe H, Gaide O, Pétrilli V, Martinon F, Contassot E, Roques S, Kummer JA, Tschopp J, French LE. 2007. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J. Invest. Dermatol. 127: 1956-1963. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"3. Martinon F, Mayor A and Tschopp J. 2009. The inflammasomes: guardians of the body. Ann. Rev. Immunol. 27: 229-265. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"4. Van Och FMM, Van Loveren H, Van Wolfswinkel JC, Machielsen AJC, Vandebriel RJ. 2005. Assessment of potency of allergenic activity of low molecular weight compounds based on IL-1α and IL-18 production by a murine and human keratinocyte cell line. Toxicology 210: 95-109. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"5. OECD 2010. Test No.442B: Skin sensitization: Local Lymph Node Assay: BrdU-ELISA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090996-en. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"6. Ade N, Leon F, Pallardy M, Pfeiffer JL, Kerdine-Romer S, Tissier MH, Bonnet PA, Fabre I Ourlin JC. 2009. HMOX1 and NQO1 genes are upregulated in response to contact sensitizers in dendritic cells and THP-1 cell line: role of the Keap1/Nrf2 pathway. Toxicol. Sci. 107: 451-460. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"7. OECD 2015. Test No442D: In vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264229822-en. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"8. Emter R, Ellis G, Natsch A. 2010. Performance of a novel keratinocyte-based reporter cell line in screen skin sensitizers in vitro. Toxicol. Appl. Pharmacol. 245: 281-290. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"9.  EURL ECVAM DB-ALM. Protocol No155: KeratinoSensTM. Available on: http://ecvam-dbalm.jrc.ec.europa.eu/. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"10. McKim JM Jr, Keller DJ III, Gorski JR. 2010. A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan. Ocul. Toxicol. 29: 171-192. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"11. Corsini E, Mitjans M, Galbiati V, Lucchi L, Galli CL, Marinovich M. 2009. Use of IL-18 production in a human keratinocyte cell line to discriminate contact sensitizers from irritants and low molecular weight respiratory allergens. Toxicol. In Vitro 23: 769-796. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"12. Mitjans M, Galbiati V, Lucchi L, Viviani B, Marinovich M, Galli CL, Corsini E. 2010. Use of IL-8 release and p38 MAPK activation in THP-1 cells to identify allergens and to assess their potency in vitro. Toxicol. In Vitro 24: 1803-1809. ").<Reference> makeItLive());
effect_downstreameffect6.getReferenceIDs().add(new Reference(effect_downstreameffect6,dataSource,"13. dos Santos GG, Reinders J, Ouwhand K, Rustemeyer T, Scheper RJ, Gibbs S. 2009. Progress on the development of human in vitro dendritic cell based assays for assessment of skin sensitizing potential of compounds. Toxicol. Appl. Pharmacol. 236: 372-382. ").<Reference> makeItLive());

effect_downstreameffect7 = new Effect_DownstreamEffect(pathway, dataSource);
effect_downstreameffect7.setTitle("Dendritic Cells, Activation");
effect_downstreameffect7.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
effect_downstreameffect7.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
effect_downstreameffect7.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect7,dataSource,"Definition","Immature epidermal dendritic cells, known as Langerhans cells, and dermal dendritic cells serve as antigen-presenting cells ([1];[2];[3];[4]). In this role, they recognize and internalize the hapten-protein complex formed during covalent binding leading to their activation. Subsequently, the dendritic cell loses its ability to seize new hapten-protein complexes and gains the potential to display the allergen-MHC-complex to naive T-cells; this process is often referred to as dendritic cell maturation. Simultaneously, under the influence of fibroblast- blood endothelial- and lymph endothelial chemokines (e.g. CCL19, CCL21) and epidermal cytokines (e.g. interleukin (IL), IL-1 α, IL-1β, IL-18, tumour necrosis factor alpha (TNF-α)) maturing dendritic cells migrate from the epidermis to the dermis of the skin and then to the proximal lymph nodes, where they can present the hapten-protein complex to T-cells via a major histocompatibility complex (MHC) molecule ([5];[6]). Dendritic cell activation, upon exposure to hapten-protein complexes also leads to functional changes in the cells. For example, there are changes in chemokine secretion, cytokine secretion and in the expression of chemokine receptors (see[3]). Additionally, during dendritic cell maturation MHC, co-stimulatory and intercellular adhesion molecules (e.g. CD40, CD86, and DC11 and CD54, respectively) are up-regulated (see[3];[4];[7]). Signal transduction cascades precede changes in expression of surface proteins markers and chemokine or cytokine secretion. In fact, there is evidence that during the response, hapten-protein complexes can react with cell surface proteins and activate mitogen-activated protein kinase signalling pathway. In particular, the biochemical pathway involving extracellulare signal-regulating kinases- the c-jun N-terminal kinases and the p38 kinases have been shown to be activated upon exposure to protein-binding chemicals[8]. These pathways are of particular importance in keratinocytes and dendritic cell response to protein-hapten complexes. Components of signal transduction pathways are kinases, which phosphorylate and dephosphorylate a variety of substrates in order to elicit a change in the expression or secretion of target molecules. As a result, components of the signal transduction cascade are thought to be biomarkers[9]. Investigations into the possible role of calcium influx as an early event in dendritic cell activation suggest that calcium influx is a second event following reactive oxygen species induction[10];[11]. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
effect_downstreameffect7.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect7,dataSource,"Measurment/detection","Omic studies \n\nGenomic and proteomic studies also have the potential to reveal biomarkers in dendritic cell-based assays. Custom designed arrays or quantitative polymerase chain reaction (PCR) of selected genes have been used to highlight the reaction of dendritic cells (see[3]). VITOSENS, an assay that uses human CD34+ progenitor-derived dendritic cells (CD34-DC), is based on the differential expression of the cAMP-responsive element modulator (CREM) and monocyte chemotactic protein-1 receptor (CCR2)[12]. Genomic signatures have been also developed for the identification of human sensitising chemicals: a biomarker signature, the Genomic Allergen Rapid Detection test (GARD) based on the human myelomonocytic cell line MUTZ-3[13] and a genomic platform, SENSIS, which consists of measuring the over-expression of 3 sets of genes, that may allow the in vitro assessment of the sensitising potential of a compound[14]. \n\nIn Vitro Assays for Cell Surface Markers, Cytokines, and Chemokines \n\nAlterations in intercellular adhesion molecules, cytokines, and chemokines are part of the immunology response which can serve as biomarkers. Since dendritic cell maturation upon exposure to hapten-protein complexes is accompanied by changes in surface marker expression, these surface markers are perceived as promising candidates as primary biomarkers of dendritic cell activation for the development of cell-based in vitro assays. While a variety of surface markers have been described to be up-regulated upon dendritic cell maturation, a review of the literature reveals that CD86 expression, followed by CD54 and CD40, are the most extensively studied intercellular adhesion and co-stimulator molecules to date. The human Cell Line Activation Test (h-CLAT) reported flow cytometry results for CD86 and CD54 expression in THP-1 cells[15];[16]. An OECD Test Guideline for the h-CLAT is currently under review. The h-CLAT protocol can be found in the EURL ECVAM Database Service on Alternative Methods to animal experimentation (DB-ALM): Protocol No158 for human Cell Line Activation Test (h-CLAT)[17]. Other studies with THP-1 cells include that of An et al. (2009). Another assay, the myeloid U937 skin sensitisation test (U-SENS), is based as well on the measurement of CD86 by flow cytometry[18];[19];[20]). In addition to that, a variety of cytokines have been studied in relationship to skin sensitizers[4]. IL-8 is a promising chemokine for distinguishing sensitisers from non-sensitisers. Quantification of IL-8 can be performed by Enzyme Linked Immunosorbent Assay, a technique that is far simpler and amenable to high throughput screening than the flow cytometry technique used to measure CD86 expression[3]. The expression of other cytokines linked to skin sensitisers include IL-1 α, IL-1β, IL-18, and TNF-α form the basis for other dendritic cell assays. \n\n<h3><span id=\"Overview_table:_How_it_is_measured_or_detected\" class=\"mw-headline\">Overview table: How it is measured or detected</span></h3>\n\n<table id=\"Event398\" class=\"wikitable\">\n\n<tbody>\n\n<tr><th>Method(s)</th><th>Reference</th><th>URL</th><th>Regulatory\n\n<p>Acceptance</p>\n\n</th><th>Validated</th><th>Non\n\n<p>Validated</p>\n\n</th></tr>\n\n<tr>\n\n<td rowspan=\"4\">h-CLAT</td>\n\n<td>draft TG under discussion at OECD</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.oecd.org/chemicalsafety/testing/Draft-new-Test-Guideline-Skin-Sensitisation-h-CLAT-July-2014.pdf\" target=\"_blank\" rel=\"nofollow\">[1]</a></td>\n\n<td rowspan=\"4\">&nbsp;</td>\n\n<td rowspan=\"4\">X</td>\n\n<td rowspan=\"4\">&nbsp;</td>\n\n</tr>\n\n<tr>\n\n<td>DB-ALM</td>\n\n<td><a class=\"external autonumber\" href=\"http://ecvam-dbalm.jrc.ec.europa.eu/beta/index.cfm/methodsAndProtocols/index?id_prot=1558\" target=\"_blank\" rel=\"nofollow\">[2]</a></td>\n\n</tr>\n\n<tr>\n\n<td>EURL ECVAM Recommendation</td>\n\n<td><a class=\"external autonumber\" href=\"https://eurl-ecvam.jrc.ec.europa.eu/news/news_docs/eurl-ecvam-recommendation-on-the-human-cell-line-activation-test-h-clat-for-skin-sensitisation-testing\" target=\"_blank\" rel=\"nofollow\">[3]</a></td>\n\n</tr>\n\n<tr>\n\n<td>Ashiga et al., 2015</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.ncbi.nlm.nih.gov/pubmed/20822320\" target=\"_blank\" rel=\"nofollow\">[4]</a></td>\n\n</tr>\n\n<tr>\n\n<td>Genomic Allergen Rapid Detection test (GARD)</td>\n\n<td>Johansson et al., 2013</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.ncbi.nlm.nih.gov/pubmed/23032079\" target=\"_blank\" rel=\"nofollow\">[5]</a></td>\n\n<td>&nbsp;</td>\n\n<td>&nbsp;</td>\n\n<td>X</td>\n\n</tr>\n\n<tr>\n\n<td>VitroSens</td>\n\n<td>Hooyberghs et al., 2008</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.ncbi.nlm.nih.gov/pubmed/18466943\" target=\"_blank\" rel=\"nofollow\">[6]</a></td>\n\n<td>&nbsp;</td>\n\n<td>&nbsp;</td>\n\n<td>X</td>\n\n</tr>\n\n</tbody>\n\n</table>").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 1);
effect_downstreameffect7.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect7,dataSource," Evidence Supporting Taxonomic Applicability"," \n\n<h3><span id=\"Taxonomic_Applicability\" class=\"mw-headline\">Taxonomic Applicability</span></h3>\n\n<table id=\"Specproof\" class=\"wikitable sortable jquery-tablesorter\">\n\n<thead>\n\n<tr><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Scientific Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Evidence</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Links</th></tr>\n\n</thead>\n\n<tbody>\n\n<tr>\n\n<td>mouse</td>\n\n<td>Mus musculus</td>\n\n<td><a title=\"Event:398\" href=\"https://aopwiki.org/wiki/index.php/Event:398#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n<tr>\n\n<td>human</td>\n\n<td>Homo sapiens</td>\n\n<td><a title=\"Event:398\" href=\"https://aopwiki.org/wiki/index.php/Event:398#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n</tbody>\n\n</table>\n\nThe main in vitro assays currently used and based on dendritic cells activation use human dendritic-cell-like cell lines (e.g. THP-1, U-937, MTZ-3)[3]. In addition to that some assays were performed on murine models[5]. ").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 2);
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"1.Ryan CA, Gerberick GF, Gildea LA, Hulette BC, Bettis CJ, Cumberbatch M, Dearman RJ, Kimber I. 2005. Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment. Toxicol. Sci. 88: 4-11. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"2.  Ryan CA, Kimber I, Basketter, DA, Pallardy M, Gildea LA, Gerberick GF. 2007. Dendritic cells and skin sensitisation. Biological roles and uses in hazard identification. Toxicol. Appl. Pharmacol. 221: 384-394. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"3. dos Santos GG, Reinders J, Ouwhand K, Rustemeyer T, Scheper RJ, Gibbs S. 2009. Progress on the development of human in vitro dendritic cell based assays for assessment of skin sensitizing potential of compounds. Toxicol. Appl. Pharmacol. 236: 372-382. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"4. Kimber I, Basketter DA, Gerberick GF, Ryan CA, Dearman, R.J. 2011. Chemical allergy: Translating biology into hazard characterization. Toxicol. Sci. 120(S1): S238-S268.  ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"5. OECD 2010. Test No.442B: Skin sensitization: Local Lymph Node Assay: BrdU-ELISA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090996-en. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"6. Ouwehand K, Santegoets SJAM, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S. 2008. CXCL12 is essential for migration of activated Langerhans cells for epidermis to dermis. Eur. J. Immunol. 38: 3050-3059. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"7. Vandebriel RJ and van Loveren H. 2010. Non-animal sensitisation testing: State-of-the-art. Crit. Rev. Toxicol. 40: 389-404. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"8. Trompezinski S, Migdal C, Tailhardat M, Le Varlet B, Courtellemont P, Haftek M and Serres M. 2008. Charaterization of early events involved in human dendritic cell maturation induced by sensitizers: cross talk between MAPK signalling pathways. Toxicol. Appl. Pharmacol. 230: 397-406. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"9. Lambrechts N, Vanheel H, Hooyberghs J, De Boever P, Witters H, Van Den Heuval R, Van Tendeloom V, Nelissen I, Schoeters G. 2010. Gene markers in dendritic cells unravel pieces of the skin sensitisation puzzle. Toxicol. Letters 196: 95-103. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"10. Migdal C, Tailhardat M, Courtellemont P, Haftek M, Serres M. 2010. Responsiveness of human monocyte-derived dendritic cells to thimerosal and mercury derivatives. Toxicol. Appl. Pharmacol. 246: 66-73. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"11. Aeby P, Ashikaga T, Bessou-Touya S, Schapky A, Geberick F, Kern P, Marrec-Fairley M, Maxwell G, Ovigne JM, Sakaguchi H, Reisinger K, Tailhardat M, Martinozzi-Teisser S, Winkler P. 2010. Identifying and characterizing chemical skin sensitizers without animal testing; Colipa’s research and methods development program. Toxicol. In Vitro 24: 1465-1473. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"12.J Hooyberghs J, Schoeters E, Lambrechts N, Nelissen I, Witters H, Schoeters G, Van Den Heuvel R. 2008. A cell-based in vitro alternative to identify skin sensitizers by gene expression. Toxicol. Appl. Pharmacol. 231: 103-111. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"13.dos Santos GG, Reinders J, Ouwhand K, Rustemeyer T, Scheper RJ, Gibbs S. 2009. Progress on the development of human in vitro dendritic cell based assays for assessment of skin sensitizing potential of compounds. Toxicol. Appl. Pharmacol. 236: 372-382. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"14. Groux H and Sabatier JM. 2010. Polypeptides for the in vitro assessment of the sensitising potential of a test compound. International Application Patent No.: PCT/EP2010/055895. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"15. Sakaguchi H, Ashikaga T, Miyazawa M, Kosaka N, Ito Y, Yoneyama K, Sono S, Itagaki H, Toyoda H, Suzuki H. 2009. The relationship between CD86/CD54 expression and THP-1 cell viability in an in vitro skin sensitisation test-human cell line activation test (h-CLAT). Cell Biol. Toxicol. 25: 109-126. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"16. Ashikaga T, Sakaguchi H, Sono S, Kosaka N, Ishikawa M, Nukada Y, Miyazawa M, Ito Y, Nishiyama N, Itagaki H. 2010. A comparative evaluation of in vitro skin sensitisation tests: the human cell-line activation test (h-CLAT) versus the local lymph node assay (LLNA). Altern. Lab. Anim. 38:275-84. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"17. EURL ECVAM DB-ALM. Protocol No158: Human Cell Line Activation Test (h-CLAT) Available on: http://ecvam-dbalm.jrc.ec.europa.eu/. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"18. Ade N, Martinozzi-Teissier S, Pallaardy M, Rousset F. 2006. Activation of U937 cells by contact sensitizers: CD86 expression is independent of apoptosis. J. Immunotoxicol. 3: 189-197. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"19  Python F, Goebel C, Aeby P. 2007. Assessment of the U937 cell line for detection of contact allergens. Toxicol. Appl. Pharmacol. 220: 113-124. ").<Reference> makeItLive());
effect_downstreameffect7.getReferenceIDs().add(new Reference(effect_downstreameffect7,dataSource,"20. Ovigne JM, Martinozzi-Teissier S, Verda D, Abdou D, Piroird C, Ade N, Rousset F. 2008. The MUSST for in vitro skin sensitisation prediction: Applicability domains and complementary protocols to adapt to the physico-chemical diversity of chemicals. Toxicology Letters, 180: Supplement 1, 5, S216. ").<Reference> makeItLive());

effect_downstreameffect10 = new Effect_DownstreamEffect(pathway, dataSource);
effect_downstreameffect10.setTitle("T-cells, Activation/Proliferation");
effect_downstreameffect10.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "organ");
effect_downstreameffect10.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LIFE_STAGE.DIMENSION_INDEX, "adult");
effect_downstreameffect10.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
effect_downstreameffect10.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect10,dataSource,"Definition","T-cells are typically affected by protein-hapten complexes presented by dendritic cells on Major Histocompatibility Complex (MHC) molecules. Molecular understanding of this process has improved in recent years (see[1]). Briefly, MHC molecules are membrane proteins which present the small peptide antigens placed in a “groove” of the MHC molecule during its intracellular synthesis and transport to the cell surface. In the context of the MHC molecular on the cell surface, the small peptide antigen is recognized via the T-cell receptors as self or non-self (e.g. foreign). If this peptide is a foreign peptide, such as part of a protein-hapten complex, the T-cell will be activated to form a memory T-cell, which subsequently proliferates. If reactivated upon presentation by skin dendritic cells, these memory T-cells will induce allergic contact dermatitis[2]. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
effect_downstreameffect10.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect10,dataSource,"Measurment/detection","Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible?  \n\nMost protocols recognize the importance of the process of antigen-presentation, so in vitro T-cell-based assays are typically co-cultures of allergen-treated dendritic cells and modified T-lymphocytes with expression of selected biomarkers (e.g. interferon gamma), or T-cell proliferation being the reported outcome. Much of this work has been reviewed by Martin et al[1]. It should be remembered that lymph node cell proliferation is the basis for the in vivo mouse Local Lymph Node Assay (LLNA). OECD TG 429 is the validated test guideline for the Skin Sensitisation: Local Lymph Node Assay[3] together with its two non-radioactive modifications (LLNA-DA TG442A[4] and LLNA-BrdU ELISA TG 442B[5]). \n\n<h3><span id=\"Overview_table:_How_it_is_measured_or_detected\" class=\"mw-headline\">Overview table: How it is measured or detected</span></h3>\n\n<table id=\"Event272\" class=\"wikitable\"><caption><strong>Overview</strong></caption>\n\n<tbody>\n\n<tr><th>Method(s)</th><th>Reference</th><th>URL</th><th>Regulatory\n\n<p>Acceptance</p>\n\n</th><th>Validated</th><th>Non\n\n<p>Validated</p>\n\n</th></tr>\n\n<tr>\n\n<td rowspan=\"3\">Local Lymph Node Assay (LLNA)</td>\n\n<td>TG 429</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.oecd-ilibrary.org/environment/test-no-429-skin-sensitisation_9789264071100-en\" target=\"_blank\" rel=\"nofollow\">[1]</a></td>\n\n<td rowspan=\"3\">X</td>\n\n<td rowspan=\"3\">X</td>\n\n<td rowspan=\"3\">&nbsp;</td>\n\n</tr>\n\n<tr>\n\n<td>TG 442A LLNA:DA</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.oecd-ilibrary.org/environment/test-no-442a-skin-sensitization_9789264090972-en\" target=\"_blank\" rel=\"nofollow\">[2]</a></td>\n\n</tr>\n\n<tr>\n\n<td>TG 442B LLNA: BrdU-ELISA</td>\n\n<td><a class=\"external autonumber\" href=\"http://www.oecd-ilibrary.org/environment/test-no-442b-skin-sensitization_9789264090996-en\" target=\"_blank\" rel=\"nofollow\">[3]</a></td>\n\n</tr>\n\n</tbody>\n\n</table>").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 1);
effect_downstreameffect10.getDescriptionIDs().set(new DescriptionSection(effect_downstreameffect10,dataSource," Evidence Supporting Taxonomic Applicability"," <h3><span id=\"Taxonomic_Applicability\" class=\"mw-headline\">Taxonomic Applicability</span></h3>\n\n<table id=\"Specproof\" class=\"wikitable sortable jquery-tablesorter\">\n\n<thead>\n\n<tr><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Scientific Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Evidence</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Links</th></tr>\n\n</thead>\n\n<tbody>\n\n<tr>\n\n<td>human</td>\n\n<td>Homo sapiens</td>\n\n<td><a title=\"Event:272\" href=\"https://aopwiki.org/wiki/index.php/Event:272#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n<tr>\n\n<td>mouse</td>\n\n<td>Mus musculus</td>\n\n<td><a title=\"Event:272\" href=\"https://aopwiki.org/wiki/index.php/Event:272#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10090\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n</tbody>\n\n</table>\n\nSome in vitro assays have been developed using human T cells[1]. Lymph node proliferation is the basis for the in vivo mouse LLNA. ").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 2);
effect_downstreameffect10.getReferenceIDs().add(new Reference(effect_downstreameffect10,dataSource,"1. Martin SF, Esser PR, Schmucker S, Dietz L, Naisbitt DJ, Park BK, Vocanson M, Nicolas JF, Keller M, Pichler WJ, Peiser M, Luch A, Wanner R, Maggi E, Cavani A, Rustemeyer T, Richter A, Thierse HJ, Sallusto F. 2010. T-cell recognition of chemical, protein allergens and drugs; toward the development of in vitro assays. Cell. Mol. Life Sci. 67: 4171-4184. ").<Reference> makeItLive());
effect_downstreameffect10.getReferenceIDs().add(new Reference(effect_downstreameffect10,dataSource,"2. Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. 2009. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64: 1699-1714. ").<Reference> makeItLive());
effect_downstreameffect10.getReferenceIDs().add(new Reference(effect_downstreameffect10,dataSource,"3. OECD 2010. Test No.429: Skin sensitization: Local Lymph Node Assay. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264071100-en. ").<Reference> makeItLive());
effect_downstreameffect10.getReferenceIDs().add(new Reference(effect_downstreameffect10,dataSource,"4.  OECD 2010. Test No442A: Skin sensitization: Local Lymph Node Assay:DA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090972-en. ").<Reference> makeItLive());
effect_downstreameffect10.getReferenceIDs().add(new Reference(effect_downstreameffect10,dataSource,"OECD 2010. Test No.442B: Skin sensitization: Local Lymph Node Assay: BrdU-ELISA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090996-en. ").<Reference> makeItLive());

effect_adverseoutcome12 = new Effect_AdverseOutcome(pathway, dataSource);
effect_adverseoutcome12.setTitle(" skin, sensitisation");
effect_adverseoutcome12.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "individual");
effect_adverseoutcome12.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
effect_adverseoutcome12.getDescriptionIDs().set(new DescriptionSection(effect_adverseoutcome12,dataSource,"Definition","Skin sensitisation is an immunological process that is described in two phases: the induction of sensitisation and the subsequent elicitation of the immune reaction. A sensitised subject has the capacity to mount a more accelerated secondary response to the same chemical. Upon reaching an unknown threshold number of hapten-specific T cells an individual will be said to be sensitised and will elicit a T cell-mediated eczematous skin reaction (termed allergic contact dermatitis, ACD) at the site of sensitiser re-exposure. Above the threshold, the severity of the adverse effect is assumed to increase proportionally to the dose, so the total dose per area of skin (e.g. μg/cm2) is the critical exposure determinant. In this regard, animal data is consistent with human clinical data[1]. The allergic reaction causes inflammation of the skin manifested by varying degrees of erythema, oedema, and vesiculation. It takes up to one week or more for individuals to develop specific sensitivity to a new allergen following exposure. An individual who never has been sensitised to a substance may develop only a mild dermatitis 2 weeks following the initial exposure but typically develops severe dermatitis within 1-2 days of the second and subsequent exposures[2]. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
effect_adverseoutcome12.getDescriptionIDs().set(new DescriptionSection(effect_adverseoutcome12,dataSource,"Measurment/detection","[3]Human sensitisation testing is conducted with the Human Repeat Insult Patch Test (HRIPT), as described by McNamee et al.[4];[5]. Skin biopsy may help to confirm the diagnosis and exclude other disorders. \n\nAnimal models have been developed to assess the sensitisation potential of chemicals. Adler et al. (2011) have reviewed animal test methods for skin sensitisation[6]. Briefly, among these in vivo assays are the guinea-pig occluded patch test[7];[8], the Magnusson-Kligman guinea pig maximization test[7];[9];[10], and the murine Local Lymph Node Assay[11];[12];[13]. Using LLNA data, sensitisers can be grouped into potency groups (e.g. extreme, strong, moderate, weak and non-sensitisers). However, as noted by Basketter et al. [14], the LLNA is not without limitations. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 1);
effect_adverseoutcome12.getDescriptionIDs().set(new DescriptionSection(effect_adverseoutcome12,dataSource," Affected Organs"," <h3>&nbsp;</h3>\n\n<table id=\"Organproof\" class=\"wikitable sortable jquery-tablesorter\">\n\n<thead>\n\n<tr><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Synonym</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Scientific Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Evidence</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Links</th></tr>\n\n</thead>\n\n<tbody>\n\n<tr>\n\n<td>skin</td>\n\n<td>zone of skin</td>\n\n<td><a class=\"external text\" href=\"http://www.ontobee.org/browser/rdf.php?o=UBERON&amp;iri=http://purl.obolibrary.org/obo/UBERON_0000014\" target=\"_blank\" rel=\"nofollow\">Ontobee</a></td>\n\n</tr>\n\n</tbody>\n\n</table>").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 2);
effect_adverseoutcome12.getDescriptionIDs().set(new DescriptionSection(effect_adverseoutcome12,dataSource," Evidence Supporting Taxonomic Applicability"," \n\n<h3><span id=\"Taxonomic_Applicability\" class=\"mw-headline\">Taxonomic Applicability</span></h3>\n\n<table id=\"Specproof\" class=\"wikitable sortable jquery-tablesorter\">\n\n<thead>\n\n<tr><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Scientific Name</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Evidence</th><th class=\"headerSort\" tabindex=\"0\" title=\"Sort ascending\">Links</th></tr>\n\n</thead>\n\n<tbody>\n\n<tr>\n\n<td>human</td>\n\n<td>Homo sapiens</td>\n\n<td><a title=\"Event:827\" href=\"https://aopwiki.org/wiki/index.php/Event:827#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=9606\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n<tr>\n\n<td>mouse</td>\n\n<td>Mus musculus domesticus</td>\n\n<td><a title=\"Event:827\" href=\"https://aopwiki.org/wiki/index.php/Event:827#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10092\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n<tr>\n\n<td>guinea pig</td>\n\n<td>Cavia porcellus</td>\n\n<td><a title=\"Event:827\" href=\"https://aopwiki.org/wiki/index.php/Event:827#Evidence_Supporting_Taxonomic_Applicability\">Strong</a></td>\n\n<td><a class=\"external text\" href=\"http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=10141\" target=\"_blank\" rel=\"nofollow\">NCBI</a></td>\n\n</tr>\n\n</tbody>\n\n</table>\n\nIn vivo studies remain the basis of assessing the sensitisation potential of chemicals (see [6]). As previously noted, human sensitisation testing is conducted with the HRIPT[4]. Other in vivo methods include the guinea-pig occluded patch test[6];[15], the Magnusson- Kligman guinea-pig maximization test [16] and the mouse LLNA[11];[12];[13]. ").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 3);
effect_adverseoutcome12.getDescriptionIDs().set(new DescriptionSection(effect_adverseoutcome12,dataSource," Regulatory Examples Using This Adverse Outcome"," Skin sensitisation is an endpoint that needs to be assessed within: \n\n- CLP Regulation (EC) No1272/2008 for \"Classification, Labelling and Packaging of substances and Mixtures\", \n\n- REACH Regulation (EC) No1907/2006 concerning the Registration, Evaluation, Authorization and Restriction of Chemicals, \n\n- PPP Regulation (EC) No1107/2009 concerning the placing of plant protection products on the market, \n\n- Biocidal Products Regulation (BPR) (EU) No528/2012 concerning the making available on the market and use of biocidal products, \n\n- Cosmetics Regulation (EC) No1223/2009. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 4);
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"1. Api AM, Basketter DA, Cadby PA, Cano MF, Ellis G, Gerberick GF, Griem P, McNamee PM, Ryan CA, Safford B. 2008. Dermal sensitisation quantitative risk assessment (QRA) for fragrance ingredients. Regul Toxicol Pharmacol. 52(1):3-23. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"2. Hogan DJ and James WD.2015. Allergic Contact Dermatitis Workup Updated: Apr 22, 2015. Available on: http://emedicine.medscape.com/article/1049216-overview accessed 17.9.2015 ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"3.	Bernstein IL, Li JT, Bernstein DI et al.2008. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 100(3 Suppl 3):S1-148. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"4. McNamee PM, Api AM, Basketter DA, Frank Gerberick G, Gilpin DA, Hall BM, Jowsey I, Robinson MK.2008. A review of critical factors in the conduct and interpretation of the human repeat insult patch test. Regul Toxicol Pharmacol. 52(1):24-34. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"5. OECD 2010. Test No.442B: Skin sensitization: Local Lymph Node Assay: BrdU-ELISA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090996-en. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"6. Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Ejner-Andersen K, Angers- Loustau A, Aptula A, Bal-Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Batista Leite S, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tahti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM. 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 85: 367-485. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"7. OECD 1992. Test No. 406: Skin Sensitisation, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing. doi: 10.1787/9789264070660-en. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"8. Buehler EV. 1965. Delayed hypersensitivity in the guinea pig. Arch. Dermatol. 91: 171-177. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"9. Magnusson B and Kligman AM. 1970. Allergic Contact Dermatitis in the Guinea Pig. Identification of Contact Allergens. Charles C Thomas; Springfield, IL USA. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"10. Maurer T, Arthur A and Bentley P. 1994. Guinea-pig contact sensitisation assays. Toxicology 93: 47-54. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"11. OECD 2010. Test No429: Skin Sensitisation: Local Lymph Node Assay, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing. doi: 10.1787/9789264071100-en ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"12. OECD 2010b. Test No442A: Skin Sensitisation: Local Lymph Node Assay: DA, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing. doi: 10.1787/9789264090972- en. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"13. dos Santos GG, Reinders J, Ouwhand K, Rustemeyer T, Scheper RJ, Gibbs S. 2009. Progress on the development of human in vitro dendritic cell based assays for assessment of skin sensitizing potential of compounds. Toxicol. Appl. Pharmacol. 236: 372-382. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"14. Basketter DA, McFadden JF, Gerberick F, Cochshott A and Kimber I. 2009. Nothing is perfect, not even the local lymph node assay: a commentary and the implications for REACH. Contact Dermat. 60: 65-69. ").<Reference> makeItLive());
effect_adverseoutcome12.getReferenceIDs().add(new Reference(effect_adverseoutcome12,dataSource,"15.	OECD 1992. Test No 406: Skin Sensitisation, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing. doi: 10.1787/9789264070660-en ").<Reference> makeItLive());

test_inchemico14 = new Test_InChemico(pathway, dataSource);
test_inchemico14.setTitle("OECD TG 442D-ARE-Nrf2 Luciferase Test Method");
test_inchemico14.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
test_inchemico14.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_inchemico14.getDescriptionIDs().set(new DescriptionSection(test_inchemico14,dataSource,"Assay Description","n-vitro test method description: This Test Guideline (TG) provides an in vitro procedure (the ARE-Nrf2 luciferase test method) used for supporting the discrimination between skin sensitisers and non-sensitisers in accordance with the UN GHS.\n\nThe second key event on the adverse outcome pathway leading to skin sensitisation takes place in the keratinocytes and includes inflammatory responses as well as gene expression associated with specific cell signalling pathways such as the antioxidant/electrophile response element (ARE)-dependent pathways. The test method described in this Test Guideline (ARE-Nrf2 luciferase test method) is proposed to address this second key event. The cell line contains the luciferase gene under the transcriptional control of a constitutive promoter fused with an ARE element from a gene that is known to be up-regulated by contact sensitisers. The luciferase signal reflects the activation by sensitisers of endogenous Nrf2 dependent genes. This allows quantitative measurement (by luminescence detection) of luciferase gene induction, using well established light producing luciferase substrates, as an indicator of the activity of the Nrf2 transcription factor in cells following exposure to electrophilic test substances.\n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_inchemico14.getReferenceIDs().add(new Reference(test_inchemico14,dataSource,"http://www.oecd-ilibrary.org/environment/test-no-442d-in-vitro-skin-sensitisation_9789264229822-en").<Reference> makeItLive());

test_invitro18 = new Test_InVitro(pathway, dataSource);
test_invitro18.setTitle("OECD 442E: Human Cell Line Activation Test (h-CLAT) ");
test_invitro18.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
test_invitro18.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_invitro18.getDescriptionIDs().set(new DescriptionSection(test_invitro18,dataSource,"Assay Description","n-vitro test method description: This Test Guideline (TG) provides an in vitro procedure (the human cell Line Activation Test h-CLAT method) used for supporting the discrimination between skin sensitisers and non-sensitisers in accordance with the UN GHS. The h-CLAT method is proposed to address the third key event of the skin sensitisation AOP by quantifying changes in the expression of cell surface markers associated with the process of activation of monocytes and dendritic cells (DC) (i.e. CD86 and CD54), in the human monocytic leukaemia cell line THP-1, following exposure to sensitising test chemical. These surface molecules are typical markers of monocytic THP-1 activation and may mimic DC activation, which plays a critical role in T-cell priming. The changes of surface marker expression are measured by flow cytometry following cell staining with fluorochrome-tagged antibodies. The relative fluorescence intensity of surface markers compared to solvent/vehicle control are calculated and used in the prediction model, to support the discrimination between sensitisers and non-sensitisers.\n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_invitro18.getReferenceIDs().add(new Reference(test_invitro18,dataSource,"http://www.oecd-ilibrary.org/environment/test-no-442e-in-vitro-skin-sensitisation_9789264264359-en").<Reference> makeItLive());

test_invitro19 = new Test_InVitro(pathway, dataSource);
test_invitro19.setTitle("Genomic Allergen Rapid Detection test (GARD)   ");
test_invitro19.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
test_invitro19.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_invitro19.getDescriptionIDs().set(new DescriptionSection(test_invitro19,dataSource,"Assay Description","In-vitro test method description: Identifies a signature of predictive genes, which are differentially regulated in the human myeloid cell-line MUTZ-3 when stimulated with sensitizing compounds compared to non-sensitizing compounds. \n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_invitro19.getReferenceIDs().add(new Reference(test_invitro19,dataSource,"Borrebaeck CA and Wingren C. 2009. Design of high-density antibody microarrays for disease proteomics: key technological issues. J. Proteomics 72: 928-935. ").<Reference> makeItLive());
test_invitro19.getReferenceIDs().add(new Reference(test_invitro19,dataSource,"Johansson H, Albrekt AS, Borrebaeck CA, Lindstedt M. 2013. The GARD assay for assessment of chemical skin sensitizers.Toxicol In Vitro. 2013 Apr;27(3):1163-9. doi: 10.1016/j.tiv.2012.05.019. Epub 2012 Sep 29.").<Reference> makeItLive());

test_invitro20 = new Test_InVitro(pathway, dataSource);
test_invitro20.setTitle("VitoSens");
test_invitro20.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
test_invitro20.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_invitro20.getDescriptionIDs().set(new DescriptionSection(test_invitro20,dataSource,"Assay Description","In-vitro test method description: VITOSENS, an assay that uses human CD34+ progenitor-derived dendritic cells (CD34-DC), is based on the differential expression of the cAMP-responsive element modulator (CREM) and monocyte chemotactic protein-1 receptor (CCR2).\n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_invitro20.getReferenceIDs().add(new Reference(test_invitro20,dataSource,"Hooyberghs J, Schoeters E, Lambrechts N, Nelissen I, Witters H, Schoeters G, Van Den Heuvel R. 2008. A cell-based in vitro alternative to identify skin sensitizers by gene expression. Toxicol. Appl. Pharmacol. 231: 103-111. ").<Reference> makeItLive());

test_inchemico23 = new Test_InChemico(pathway, dataSource);
test_inchemico23.setTitle("TG 442C-DPRA");
test_inchemico23.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "molecular");
test_inchemico23.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_inchemico23.getDescriptionIDs().set(new DescriptionSection(test_inchemico23,dataSource,"Assay Description","In-chemico test method description\n\n• Description of the principles of measurement: The DPRA is an in chemico method designed to support the discrimination between skin sensitising and non-sensitising chemicals by quantifying the reactivity of chemicals towards model synthetic peptides containing either lysine or cysteine. The DPRA is addressing the process of haptenation (i.e. covalent binding of electrophilic chemicals to skin proteins).\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_inchemico23.getReferenceIDs().add(new Reference(test_inchemico23,dataSource,"1. http://www.oecd-ilibrary.org/environment/test-no-442c-in-chemico-skin-sensitisation_9789264229709-en").<Reference> makeItLive());

test_inchemico28 = new Test_InChemico(pathway, dataSource);
test_inchemico28.setTitle("GSH depletion");
test_inchemico28.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "molecular");
test_inchemico28.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_inchemico28.getDescriptionIDs().set(new DescriptionSection(test_inchemico28,dataSource,"Assay Description","In-chemico test method description: While methionine, histidine, and serine all possess nucleophilic groups that are found in skin proteins, the –SH group of cysteine and the ε-NH2 group of lysine are the most often studied. Soft electrophilic interactions involving the thiol group can be modelled with small molecules. Glutathione (GSH; L-γ-glutamyl-L-cysteinyl-glycine) is the most widely used model nucleophile in soft electrophilic reactivity assays. \n\n• Description of the principles of measurement: Typically, chemicals are incubated with GHS and, after a defined reaction time, the concentration of free thiol groups is measured\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_inchemico28.getReferenceIDs().add(new Reference(test_inchemico28,dataSource,"Schwöbel JAH, Koleva YK, Bajot F, Enoch SJ, Hewitt M, Madden JC, Roberts DW, Schultz TW and Cronin MTD. 2011. Measurement and estimation of electrophilic reactivity for predictive toxicology. Chem. Rev. 111: 2562-2596. ").<Reference> makeItLive());
test_inchemico28.getReferenceIDs().add(new Reference(test_inchemico28,dataSource,"  Kato H, Okamoto M, Yamashita K, Nakamura Y, Fukumori Y, Nakai K, Kaneko H. 2003. Peptide-binding assessment using mass spectrometry as a new screening method for skin sensitization. J. Toxicol. Sci. 28: 19-24. ").<Reference> makeItLive());
test_inchemico28.getReferenceIDs().add(new Reference(test_inchemico28,dataSource,"Schultz TW, Yarbrough JW, Woldemeskel M. 2005. Toxicity to Tetrahymena and abiotic thiol reactivity of aromatic isothiocyanates. Cell. Biol. Toxicol. 21: 181-189. ").<Reference> makeItLive());
test_inchemico28.getReferenceIDs().add(new Reference(test_inchemico28,dataSource,"Böhme A, Thaens D, Paschke A, Schüürmann G. 2009. Kinetic glutathione chemoassay to quantify thiol reactivity of organic electrophiles – Application to α, β-unsaturated ketones, acrylates, and propiolates, Chem. Res. Toxicol. 22: 742-750. ").<Reference> makeItLive());

test_inchemico30 = new Test_InChemico(pathway, dataSource);
test_inchemico30.setTitle("Cytokine production ");
test_inchemico30.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
test_inchemico30.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_inchemico30.getDescriptionIDs().set(new DescriptionSection(test_inchemico30,dataSource,"Assay Description","In-vitro test method description\n\n• Description of the principles of measurement: n vitro assays based on IL-18 induction in human keratinocytes (cell line NCTC 2544)[11] or IL-8 induction in THP-1 cells[12] have also been developed to identify allergens. Other studies have described chemokines (e.g. CCL2, CCL4) and receptor (e.g. CCR7) (see[13]). \n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_inchemico30.getReferenceIDs().add(new Reference(test_inchemico30,dataSource,"11. Corsini E, Mitjans M, Galbiati V, Lucchi L, Galli CL, Marinovich M. 2009. Use of IL-18 production in a human keratinocyte cell line to discriminate contact sensitizers from irritants and low molecular weight respiratory allergens. Toxicol. In Vitro 23: 769-796. ").<Reference> makeItLive());
test_inchemico30.getReferenceIDs().add(new Reference(test_inchemico30,dataSource,"12. Kato H, Okamoto M, Yamashita K, Nakamura Y, Fukumori Y, Nakai K, Kaneko H. 2003. Peptide-binding assessment using mass spectrometry as a new screening method for skin sensitization. J. Toxicol. Sci. 28: 19-24. ").<Reference> makeItLive());
test_inchemico30.getReferenceIDs().add(new Reference(test_inchemico30,dataSource,"13. dos Santos GG, Reinders J, Ouwhand K, Rustemeyer T, Scheper RJ, Gibbs S. 2009. Progress on the development of human in vitro dendritic cell based assays for assessment of skin sensitizing potential of compounds. Toxicol. Appl. Pharmacol. 236: 372-382. ").<Reference> makeItLive());

test_inchemico32 = new Test_InChemico(pathway, dataSource);
test_inchemico32.setTitle("Induction of ARE/EpRE-dependent pathways");
test_inchemico32.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
test_inchemico32.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_inchemico32.getDescriptionIDs().set(new DescriptionSection(test_inchemico32,dataSource,"Assay Description","In-vito test method description: Activation of gene expression under control of ARE/EpRE-dependent pathways.\n\n• Description of the principles of measurement: Can vary. Examples  include measurement of luciferase activity in stably transfected cell lines (8)  or quantitative realtime polymerase chain reaction measurements of the relative abundance of mRNA for selected genes in human skin cells (10) whose expression is controlled by one of the three following pathways: Keap1/Nrf 2/ARE/EpRE, ARNT/AhR/XRE, and Nrf1/MTF/MRE.\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_inchemico32.getReferenceIDs().add(new Reference(test_inchemico32,dataSource,"8. Emter R, Ellis G, Natsch A. 2010. Performance of a novel keratinocyte-based reporter cell line in screen skin sensitizers in vitro. Toxicol. Appl. Pharmacol. 245: 281-290. ").<Reference> makeItLive());
test_inchemico32.getReferenceIDs().add(new Reference(test_inchemico32,dataSource,"10. McKim JM Jr, Keller DJ III, Gorski JR. 2010. A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan. Ocul. Toxicol. 29: 171-192. ").<Reference> makeItLive());

test_inchemico34 = new Test_InChemico(pathway, dataSource);
test_inchemico34.setTitle("SENSIS");
test_inchemico34.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "cellular");
test_inchemico34.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_inchemico34.getDescriptionIDs().set(new DescriptionSection(test_inchemico34,dataSource,"Assay Description","In-chemico test method description: SENSIS, which consists of measuring the over-expression of 3 sets of genes, that may allow the in vitro assessment of the sensitising potential of a compound\n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_inchemico34.getReferenceIDs().add(new Reference(test_inchemico34,dataSource,"Groux H and Sabatier JM. 2010. Polypeptides for the in vitro assessment of the sensitising potential of a test compound. International Application Patent No.: PCT/EP2010/055895. ").<Reference> makeItLive());

test_invivo36 = new Test_InVivo(pathway, dataSource);
test_invivo36.setTitle(" TG 429 - LLNA");
test_invivo36.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "organ");
test_invivo36.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_invivo36.getDescriptionIDs().set(new DescriptionSection(test_invivo36,dataSource,"Assay Description","In-vivo test method description The basic principle underlying the Local Lymph Node Assay (LLNA) in mouse is that sensitizers induce a primary proliferation of lymphocytes in the auricular lymph nodes draining the site of chemical application. This proliferation is proportional to the dose applied and provides a measurement of sensitisation. The method described is based on the use of radioactive labelling to measure cell proliferation. A minimum of four animals is used per dose group, with a minimum of three concentrations of the test substance, plus a negative control group treated with the vehicle only, and a positive control, as appropriate. The experimental schedule of the assay is during 6 days. Thereafter, the animals are killed and a cell suspension of lymph node cells is prepared. The incorporation of 3H-methyl thymidine is measured by ¦Â-scintillation counting as disintegrations per minute (DPM). The Test Guideline includes performance standards that can be used to evaluate the validation status of new and/or modified test methods that are functionally and mechanistically similar to the LLNA. A reduced LLNA approach which could use up to 40% fewer animals is also described as an option. This study includes: measurements (weighing, DPM), and clinical daily observations. Results are expressed as the Stimulation Index (SI).The SI is obtained by calculation and should be ¡Ý3 before classification of the test material as a skin sensitizer is warranted.\n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_invivo36.getReferenceIDs().add(new Reference(test_invivo36,dataSource,"OECD 2010. Test No429: Skin Sensitisation: Local Lymph Node Assay, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing. doi: 10.1787/9789264071100-en ").<Reference> makeItLive());

test_invivo38 = new Test_InVivo(pathway, dataSource);
test_invivo38.setTitle("TG442A, 442B - LLNA DA, LLNA BrdU ELISA");
test_invivo38.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "organ");
test_invivo38.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_invivo38.getDescriptionIDs().set(new DescriptionSection(test_invivo38,dataSource,"Assay Description","In-vivo test method description: Non-radioactive modifications of OECD 429.\n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_invivo38.getReferenceIDs().add(new Reference(test_invivo38,dataSource,"OECD 2010. Test No442A: Skin sensitization: Local Lymph Node Assay:DA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090972-en. ").<Reference> makeItLive());
test_invivo38.getReferenceIDs().add(new Reference(test_invivo38,dataSource,"OECD 2010. Test No.442B: Skin sensitization: Local Lymph Node Assay: BrdU-ELISA. OECD Guidelines for the Testing of Chemicals, Section 4: Health effects. OECD Publishing. Doi: 10.1787/9789264090996-en. ").<Reference> makeItLive());

test_invivo40 = new Test_InVivo(pathway, dataSource);
test_invivo40.setTitle("HRIPT - Human Repeat Insult Patch Tests ");
test_invivo40.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "individual");
test_invivo40.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_invivo40.getDescriptionIDs().set(new DescriptionSection(test_invivo40,dataSource,"Assay Description","In-vivo test method description: Methodology for evaluation of responses indicative of induction and elicitation of skin sensitization and skin irritation in humans.\n\n• Description of the principles of measurement\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_invivo40.getReferenceIDs().add(new Reference(test_invivo40,dataSource,"McNamee PM, Api AM, Basketter DA, Frank Gerberick G, Gilpin DA, Hall BM, Jowsey I, Robinson MK.2008. A review of critical factors in the conduct and interpretation of the human repeat insult patch test. Regul Toxicol Pharmacol. 52(1):24-34. ").<Reference> makeItLive());

test_invivo42 = new Test_InVivo(pathway, dataSource);
test_invivo42.setTitle("OECD TG 406 - Guinea Pig Skin Sensitisation tests");
test_invivo42.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_LBO.DIMENSION_INDEX, "individual");
test_invivo42.getCoordinates().setValue(DefaultEffectopediaObjects.DEFAULT_SEX.DIMENSION_INDEX, "mixed");
test_invivo42.getDescriptionIDs().set(new DescriptionSection(test_invivo42,dataSource,"Assay Description","IIn-vivo test method description: This method provides information on health hazard likely to arise from exposure to test substance via intradermical injection and/or epidermical application. In this Test Guideline, the methods preferred over other are: the Guinea Pig Maximisation Test (GPMT) of Magnusson and Kligman which uses adjuvant and the non adjuvant Buehler Test. \n\n• Description of the principles of measurement: This Test Guideline is intended primarily for use with guinea pig, but recently mouse models for assessing sensitisation potential have been developed. For the GPMT at least 10 animals in the treatment group and 5 in the control group are used. For the Buehler test, a minimum of 20 animals is used in the treatment group and at least 10 animals in the control group. The test animals are initially exposed to the test substance. Following a rest period, the induction period (10-14 days), during which an immune response may develop, then the animals are exposed to a challenge dose. The GPMT is made during approximately 23-25 days, the Buehler test, during approximately 30-32 days. The concentration of test substance used for each induction exposure should be well-tolerated systemically and should be the highest to cause mild-to moderate skin irritation, for the challenge exposure the highest nonirritant dose should be used. All skin reactions and any unusual findings should be observed and recorded (other procedures may be carried out to clarify doubtful reactions).\n\n• Identification, amplification detection.\n\n• Dynamic range of detection\n\n• Number of runs/ controls\n\n...").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
test_invivo42.getReferenceIDs().add(new Reference(test_invivo42,dataSource,"OECD 1992. Test No. 406: Skin Sensitisation, OECD Guidelines for the Testing of Chemicals, Section 4: Health Effects, OECD Publishing. doi: 10.1787/9789264070660-en. ").<Reference> makeItLive());
test_invivo42.getReferenceIDs().add(new Reference(test_invivo42,dataSource,"Magnusson B and Kligman AM. 1970. Allergic Contact Dermatitis in the Guinea Pig. Identification of Contact Allergens. Charles C Thomas; Springfield, IL USA. ").<Reference> makeItLive());
test_invivo42.getReferenceIDs().add(new Reference(test_invivo42,dataSource,"Maurer T, Arthur A and Bentley P. 1994. Guinea-pig contact sensitisation assays. Toxicology 93: 47-54. ").<Reference> makeItLive());

link_chemstructtomie2 = new Link_ChemStructToMIE(pathway, dataSource,initiator_chemicalstructure1, effect_molecularinitiatingevent3);
link_chemstructtomie2.setLinkType(LinkType.DIRECT);link_chemstructtomie2.getDescriptionIDs().set(new DescriptionSection(link_chemstructtomie2,dataSource,"Definition","Molecular Interaction description:\n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
link_chemstructtomie2.getDescriptionIDs().set(new DescriptionSection(link_chemstructtomie2,dataSource,"Evidence Supporting Taxonomic Applicability","").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 1);
link_chemstructtomie2.getDescriptionIDs().set(new DescriptionSection(link_chemstructtomie2,dataSource,"Quantitative Understading","").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 2);

link_effecttoeffect4 = new Link_EffectToEffect(pathway, dataSource,effect_molecularinitiatingevent3, effect_downstreameffect6);
link_effecttoeffect4.setLinkType(LinkType.DIRECT);link_effecttoeffect4.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect4,dataSource,"Definition","Uptake of the hapten-protein complex by keratinocytes activates multiple events, including the release of pro-inflammatory cytokines and the induction of cyto-protective cellular pathways. Activation of the pro-inflammatory cytokine IL-18 results from cleavage of inactive IL-18 precursor protein by inflammasome-associated caspase-1 [1]. Hapten-protein complexes can activate the inflammasome ([2];[3]) and in so doing induce IL-18 production. Intracellular Nod-like receptors (NLR) contain sensors for a number of cellular insults. Upon activation (by a currently unknown mechanism), NLRs oligomerise form molecular complexes (i.e. inflammasomes) that are involved in the activation of inflammatory-associated caspases, including caspase-1. Keratinocyte exposure to hapten-protein complex also results in induction of antioxidant/electrophile response element ARE/EpRE-dependent pathways[4]. Briefly, reactive chemicals bind to Keap1 (Kelch-like ECH-associates protein 1) that normally inhibits the nuclear erythroid 2-related factor 2 (Nrf2). Released Nrf2 interacts with other nuclear proteins and binds to and activates ARE/EpREdependent pathways, including the cytoprotective genes NADPH-quinone oxidoreductase 1 (NQO1) and glutathione S-transferase (GSHST), among others ([4];[5]). \n\nThis KER description is based only on the OECD document 2012 and needs updating. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
ReferenceIDW<Link_EffectToEffect> link_effecttoeffect4_weigth1= new ReferenceIDW<Link_EffectToEffect>(link_effecttoeffect4, dataSource, Link_EffectToEffect.class,3.0);
link_effecttoeffect4.getDescriptionIDs().set(new DescriptionSection_Structured(link_effecttoeffect4,dataSource,"(Key) Event Relationship Weight of Evidence","• Biological Plausibility:  It is well accepted and experimentally proved that upon hapten application, keratinocytes are activated and produce various chemical mediators (e.g. TNFa, IL-1β, and prostaglandin E2) [6];[7].  \n\n• Empirical Support for Linkage: Using a series of thiol-reactive cages fluorescent haptens (i.e. bromobimanes) deployed in combination with two photon fluorescence microscopy, immunohistochemistry, and proteomics, Simonson et al. (2011) identified the possible hapten targets in proteins in human skin. Key target found were the basal keratinocytes and the keratins K5 and K14 [8]. \n\nIn a review about murine contact sensitivity, Honda et al.[14] reported that haptens can activate keratinocytes in an NLR-dependent manner. Among the NLR family, NLRP3 controls the production of proinflammatory cytokines through activation of caspase-1. Without NLRP3 or its adaptor protein ASC[2];[3];[9], the production of IL-1β and IL-18 from keratinocytes was inhibited [10];[11];[12]. \n\n• Uncertainties or Inconsistencies: Not yet discussed in AOP wiki\n\n", link_effecttoeffect4_weigth1).setFormat(ContentFormat.TEXT).<DescriptionSection_Structured> makeItLive(), 1);
link_effecttoeffect4.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect4,dataSource,"Evidence Supporting Taxonomic Applicability","Not yet discussed in AOP wiki").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 2);
link_effecttoeffect4.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect4,dataSource,"Quantitative Understading","Not yet discussed in AOP wiki").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 3);
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"1.	Martinon F, Mayor A, Tschopp J. 2009. The inflammasomes: guardians of the body. Ann. Rev. Immunol. 27: 229-265. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"2.	Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galán JE, Askenase PW, Flavell RA. 2006. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24: 317-327. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"3.	Watanabe H, Gaide O, Pétrilli V, Martinon F, Contassot E, Roques S, Kummer JA, Tschopp J, French LE. 2007. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J. Invest. Dermatol. 127: 1956-1963. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"4.	Natsch A and Emter R. 2008. Skin sensitizers induce antioxidant response element dependent genes: Application to the in vitro testing of the sensitisation potential of chemicals. Toxicol. Sci. 102: 110-119. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"5.	Ade N, Leon F, Pallardy M, Pfeiffer JL, Kerdine-Romer S, Tissier MH, Bonnet PA, Fabre I Ourlin JC. 2009. HMOX1 and NQO1 genes are upregulated in response to contact sensitizers in dendritic cells and THP-1 cell line: role of the Keap1/Nrf2 pathway. Toxicol. Sci. 107: 451-460. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"6.	Honda T, Egawa G, Grabbe S, Kabashima K. 2013. Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. J. Invest. Dermatol. 133: 303-315. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"7.	Erkes DA, Selvan RS. 2014. Hapten-induced contact hypersensitivity, autoimmune reactions, and tumour regression: plausibility of mediating antitumor immunity. J. Immunol. Res. Article ID 175265. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"8.	Simonsson C, Andersson SI, Stenfeldt AL, Bergstrom J, Bauer B, Jonsson CA, Ericson MB, Broo KS. 2011. Caged fluorescent haptens reveal the generation of cryptic epitopes in allergic contact dermatitis. J.Invest. Immunol. 131: 1486-1493. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"9.	Watanabe H, Gehrke S, Contassot E, et al. 2008. Danger signalling through the inflammasone acts as a master switch between tolerance and sensitization. J. Immunol. 180:5826-5832. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"10.	Antonopoulos C, Cumberbatch M, Dearman RJ, Daniel RJ, Kimber I, Groves RW. 2001. Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. J. Immunol. 166: 3672-3677. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"11.	Nakae S, Komiyama Y, Narumi S, Sudo K, Horai R, Tagawa Y, Matsushima K, Asano M, Iwakura Y. 2003. IL-1-induced tumor necrosis factor-alpha elicits inflammatory cell infiltration in the skin by inducing IFN-γ-inducible protein 10 in the elicitation phase of the contact hypersensitivity response. Int. Immunol. 15(2): 251-260. ").<Reference> makeItLive());
link_effecttoeffect4.getReferenceIDs().add(new Reference(link_effecttoeffect4,dataSource,"12.	Antonopoulos C, Cumberbatch M, Mee JB, Dearman RJ, Wei XQ, Liew FY, Kimber I, Groves RW. 2008. IL-18 is a key proximal mediator of contact hypersensitivity and allergen-induced Langerhans cell migration in murine epidermis. J. Leukocyte Biol. 83: 361-367. ").<Reference> makeItLive());

link_effecttoeffect5 = new Link_EffectToEffect(pathway, dataSource,effect_molecularinitiatingevent3, effect_downstreameffect7);
link_effecttoeffect5.setLinkType(LinkType.UNKNOWN);link_effecttoeffect5.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect5,dataSource,"Definition","As noted in the AOP during allergen contact with the skin, immature epidermal dendritic cells, known as Langerhans cells, and dermal dendritic cells serve as antigen-presenting cells[1];[2];[3]. In this role, they recognize and internalize the hapten-protein complex formed during covalent binding. Subsequently, the dendritic cell loses its ability to seize new hapten-protein complexes and gains the potential to display the allergen-MHC-complex to naive T-cells; this process is often referred to as dendritic cell maturation. \n\nThis KER description is based only on the OECD document 2012 and needs updating. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
ReferenceIDW<Link_EffectToEffect> link_effecttoeffect5_weigth1= new ReferenceIDW<Link_EffectToEffect>(link_effecttoeffect5, dataSource, Link_EffectToEffect.class,3.0);
link_effecttoeffect5.getDescriptionIDs().set(new DescriptionSection_Structured(link_effecttoeffect5,dataSource,"(Key) Event Relationship Weight of Evidence","• Biological Plausibility:  \n\nIt is accepted and experimentally proved that during skin sensitisation process,immature epidermal and dermal dendritic cells recognize and internalize the hapten-protein complex formed during covalent binding and subsequently mature and migrate to the local lymph nodes. [1];[2];[3]. \n\n \n\n• Empirical Support for Linkage:  \n\nThere is good agreement between the sequences of biochemical and physiological events leading to skin sensitisation (see [4];[5];[6];[7];[8];[9]). \n\nUsing an flow-cytometric assay, the influence of contact sensitisers on endocytic mechanisms in murine Langerhans cells was measured. Epidermal cell suspensions were labelled with a monoclonal antibody directed to MHC class II molecules and pH-sensitive fluorochrome-coupled second step reagents. Study reported that stimulation with well-known sensitising compounds resulted in a partial conservation of the fluorescence intensity due to the internalisation of the labelled complexes into less acidic compartments. For untreated Langerhans cells or in the presence of irritants a significant quenching of fluorescence intensity due to the internalization of the MHC-antibody complexes into acidic compartments was noticed [10]. \n\nIn the h-CLAT assay measuring the expression of CD86 and CD54 protein markers on the surface of the human monocytic leukemia cell line THP-1, the cell exposure to known non sensitisers does not increase cell biomarker expression. On the contrary, exposure to well-known sensitisers leads to an increase of the CD86 and CD54 expression[11];[12]. \n\n \n\n• Uncertainties or Inconsistencies: \n\nThe expression of other cytokines linked to skin sensitisers include IL-1 α, IL-1β, IL-18, and TNF-α form the basis for other dendritic cell assays. In general, an increase in cytokine/chemokine secretion or receptor expression is observed when sensitisers were tested but not when non-sensitisers were tested. However, there is currently only a limited number of chemicals evaluated in more than one assay and results are sometimes contradictory. \n\n", link_effecttoeffect5_weigth1).setFormat(ContentFormat.TEXT).<DescriptionSection_Structured> makeItLive(), 1);
link_effecttoeffect5.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect5,dataSource,"Evidence Supporting Taxonomic Applicability","Not yet discussed in the AOP wiki").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 2);
link_effecttoeffect5.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect5,dataSource,"Quantitative Understading","It is not known how much change in the first event is needed to impact the second. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 3);
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"1.	Ryan CA, Gerberick GF, Gildea LA, Hulette BC, Bettis CJ, Cumberbatch M, Dearman RJ and Kimber I. 2005. Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment. Toxicol. Sci. 88: 4-11. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"2.	Ryan CA, Kimber I, Basketter DA, Pallardy M, Gildea LA, Gerberick GF. 2007. Dendritic cells and skin sensitisation. Biological roles and uses in hazard identification. Toxicol. Appl. Pharmacol. 221: 384-394. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"3.	Kimber I, Basketter DA, Gerberick GF, Ryan CA and Dearman RJ. 2011. Chemical allergy: Translating biology into hazard characterization. Toxicol. Sci. 120(S1): S238-S268. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"4.	Gerberick F, Aleksic M, Basketter D, Casati S, Karlberg AT, Kern P, Kimber I, Lepoittevin JP, Natsch A, Ovigne JM, Rovida C, Sakaguchi H and Schultz T. 2008. Chemical reactivity measurement and the predictive identification of skin sensitisers. Altern. Lab. Anim.36: 215-242. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"5.	Karlberg AT, Bergström MA, Börje A, Luthman, K, Nilsson JL. 2008. Allergic contact dermatitis- formation, structural requirements, and reactivity of skin sensitizers. Chem. Res. Toxicol. 21: 53-69. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"6.	Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. 2009. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64: 1699-1714. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"7.	Aeby P, Ashikaga T, Bessou-Touya S, Schapky A, Geberick F, Kern P, Marrec-Fairley M, Maxwell G, Ovigne J-M, Sakaguchi H, Reisinger K, Tailhardat M, Martinozzi-Teisser S, Winkler P. 2010. Identifying and characterizing chemical skin sensitizers without animal testing; Colipa’s research and methods development program. Toxicol. In Vitro 24: 1465-1473. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"8.	Basketter DA and Kimber I. 2010. Contact hypersensitivity. In: McQueen, CA (ed) Comparative Toxicology Vol. 5, 2nd Ed. Elsevier, Kidlington, UK, pp. 397-411. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"9.	Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Ejner-Andersen K, Angers- Loustau A, Aptula A, Bal-Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S Coecke S Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Batista Leite S, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tahti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM. 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 85: 367-485. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"10.	Lempertz U, Kühn U, Knop J and Becker D. 1996. An approach to predictive testing of contact sensitizers in vitro by monitoring their influence on endocytic mechanisms. Internat. Arch. Allergy Immunol. 111: 64-70. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"11.	Sakaguchi H, Ashikaga T, Miyazawa M, Kosaka N, Ito Y, Yoneyama K, Sono S, Itagaki H, Toyoda H, Suzuki H. 2009. The relationship between CD86/CD54 expression and THP-1 cell viability in an in vitro skin sensitisation test-human cell line activation test (h-CLAT). Cell Biol. Toxicol. 25: 109-126. ").<Reference> makeItLive());
link_effecttoeffect5.getReferenceIDs().add(new Reference(link_effecttoeffect5,dataSource,"12.	Ashikaga T, Sakaguchi H, Sono S, Kosaka N, Ishikawa M, Nukada Y, Miyazawa M, Ito Y, Nishiyama N, Itagaki H. 2010. A comparative evaluation of in vitro skin sensitisation tests: the human cell-line activation test (h-CLAT) versus the local lymph node assay (LLNA). Altern. Lab. Anim. 38:275-84. ").<Reference> makeItLive());

link_effecttoeffect8 = new Link_EffectToEffect(pathway, dataSource,effect_downstreameffect6, effect_downstreameffect7);
link_effecttoeffect8.setLinkType(LinkType.DIRECT);link_effecttoeffect8.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect8,dataSource,"Definition","Uptake of the hapten by keratinocytes activates multiple events, including the release of pro-inflammatory cytokines (e.g. IL-18) and the induction of cyto-protective cellular pathways. Under the influence of fibroblast- blood endothelial- and lymph endothelial-chemokines (e.g. CCL19, CCL21) and epidermal cytokines (e.g. interleukin (IL), IL-1 α, IL-1β, IL-18, tumour necrosis factor alpha (TNF-α)) maturing dendritic cells migrate from the epidermis to the dermis of the skin and then to the proximal lymph nodes, where they can present the hapten-protein complex to T-cells via a major histocompatibility complex molecule ([1];[2]). \n\nThis KER description is based only on the OECD document 2012 and needs updating. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
ReferenceIDW<Link_EffectToEffect> link_effecttoeffect8_weigth1= new ReferenceIDW<Link_EffectToEffect>(link_effecttoeffect8, dataSource, Link_EffectToEffect.class,2.0);
link_effecttoeffect8.getDescriptionIDs().set(new DescriptionSection_Structured(link_effecttoeffect8,dataSource,"(Key) Event Relationship Weight of Evidence","• Biological Plausibility: \n\nKeratinocyte response activates multiple events, including the release of pro-inflammatory cytokines (e.g. IL-18) and the induction of cyto-protective cellular pathways. Under the influence of fibroblast- blood endothelial- and lymph endothelial-chemokines (e.g. CCL19, CCL21) and epidermal cytokines (e.g. IL-1α, IL-1β, IL-18, tumour necrosis factor alpha (TNFα)) maturing dendritic cells migrate from the epidermis to the dermis of the skin and then to the proximal lymph nodes. ([1];[2]).. \n\n• Empirical Support for Linkage:  \n\nMatjeka et al. (2012) exposed HaCaT cell line used as a model of human keratinocytes to skin sensitisers for one hour and then, after washed off, cocultured them with dendritic cells. Data showed that exposure of dendritic cells to chemically treated HaCaT cells led to the activation of dendritic cells measured by CD83 and CD86 upregulation [3].  \n\n• Uncertainties or Inconsistencies:\n\nNot yet discussed in the AOP Wiki\n\n", link_effecttoeffect8_weigth1).setFormat(ContentFormat.TEXT).<DescriptionSection_Structured> makeItLive(), 1);
link_effecttoeffect8.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect8,dataSource,"Evidence Supporting Taxonomic Applicability","Not yet discussed in the AOP Wiki\n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 2);
link_effecttoeffect8.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect8,dataSource,"Quantitative Understading","Not yet discussed in the AOP Wiki\n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 3);
link_effecttoeffect8.getReferenceIDs().add(new Reference(link_effecttoeffect8,dataSource,"1. Antonopoulos C, Cumberbatch M, Mee JB, Dearman RJ, Wei XQ, Liew FY, Kimber I, Groves RW. 2008. IL-18 is a key proximal mediator of contact hypersensitivity and allergen induced Langerhans cell migration in murine epidermis. J. Leukoc. Biol. 83: 361-367. ").<Reference> makeItLive());
link_effecttoeffect8.getReferenceIDs().add(new Reference(link_effecttoeffect8,dataSource,"2. Ouwehand K, Santegoets SJAM, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S. 2008. CXCL12 is essential for migration of activated Langerhans cells for epidermis to dermis. Eur. J. Immunol. 38: 3050-3059. ").<Reference> makeItLive());
link_effecttoeffect8.getReferenceIDs().add(new Reference(link_effecttoeffect8,dataSource,"3. Matjeka T, Summerfield V, Noursadeghi M, Chain BM. 2012. Chemical toxicity to keratinocytes triggers dendritic cell activation via an IL-1 path. J. Allergy Clin. Immunol. Letters to the editor:247-205. ").<Reference> makeItLive());

link_effecttoeffect9 = new Link_EffectToEffect(pathway, dataSource,effect_downstreameffect7, effect_downstreameffect10);
link_effecttoeffect9.setLinkType(LinkType.DIRECT);link_effecttoeffect9.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect9,dataSource,"Definition","Under the influence of fibroblast- blood endothelial- and lymph endothelial-chemokines (e.g. CCL19, CCL21) and epidermal cytokines (e.g. interleukin (IL), IL-1 α, IL-1β, IL-18, tumour necrosis factor alpha (TNF-α)) maturing dendritic cells migrate from the epidermis to the dermis of the skin and then to the proximal lymph nodes, where they can present the hapten-protein complex to T-cells via a major histocompatibility complex molecule ([1];[2]). T-cells are typically affected by protein-hapten complexes presented by dendritic cells on MHC molecules. Molecular understanding of this process has improved in recent years ([3]). Briefly, MHC molecules are membrane proteins which present the small peptide antigens placed in a “groove” of the MHC molecule during its intracellular synthesis and transport to the cell surface. In the context of the MHC molecular on the cell surface, the small peptide antigen is recognized via the T-cell receptors as self or non-self (e.g. foreign). If this peptide is a foreign peptide, such as part of a protein-hapten complex, the T-cell will be activated to form a memory T-cell, which subsequently proliferates ([4]). These observations are consistent with the immunological mechanism presented with this AOP, where it is assumed that for an adverse outcome to commence, a certain number of dendritic cells is required to be activated and to migrate to the nearest lymph node in order to instigate the further cascade of biological events (see[5]). \n\nThis KER description is based only on the OECD document 2012 and needs updating. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
ReferenceIDW<Link_EffectToEffect> link_effecttoeffect9_weigth1= new ReferenceIDW<Link_EffectToEffect>(link_effecttoeffect9, dataSource, Link_EffectToEffect.class,3.0);
link_effecttoeffect9.getDescriptionIDs().set(new DescriptionSection_Structured(link_effecttoeffect9,dataSource,"(Key) Event Relationship Weight of Evidence","• Biological Plausibility: \n\n It is well accepted and experimentally proved that in the local lymph node, maturedendritic cells present the hapten-protein complex to T-cells via a majorhistocompatibility complex molecule (MHC)[2];[1]. \n\nT-cells are typically affected by protein-hapten complexes presented by dendritic cells on MHC molecules. The T-cell will be then activated to form a memory T-cell, which subsequently proliferates[4]. \n\n \n\n• Empirical Support for Linkage: \n\nA recent study showed in mice model that dendritic cells coordinate the interactions that are necessary to initiate polyclonal regulatory T cells proliferation[6]. \n\n• Uncertainties or Inconsistencies:\n\nNot yet discussed in the AOP wiki\n\n", link_effecttoeffect9_weigth1).setFormat(ContentFormat.TEXT).<DescriptionSection_Structured> makeItLive(), 1);
link_effecttoeffect9.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect9,dataSource,"Evidence Supporting Taxonomic Applicability","Not yet discussed in the AOP wiki\n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 2);
link_effecttoeffect9.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect9,dataSource,"Quantitative Understading","Not yet discussed in the AOP wiki\n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 3);
link_effecttoeffect9.getReferenceIDs().add(new Reference(link_effecttoeffect9,dataSource,"1.	Antonopoulos C, Cumberbatch M, Mee JB, Dearman RJ, Wei XQ, Liew FY, Kimber I, Groves RW. 2008. IL-18 is a key proximal mediator of contact hypersensitivity and allergen induced Langerhans cell migration in murine epidermis. J. Leukoc. Biol. 83: 361-367. ").<Reference> makeItLive());
link_effecttoeffect9.getReferenceIDs().add(new Reference(link_effecttoeffect9,dataSource,"2.	Ouwehand K, Santegoets SJAM, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S. 2008. CXCL12 is essential for migration of activated Langerhans cells for epidermis to dermis. Eur. J. Immunol. 38: 3050-3059. ").<Reference> makeItLive());
link_effecttoeffect9.getReferenceIDs().add(new Reference(link_effecttoeffect9,dataSource,"3.	Martin SF, Esser PR, Schmucker S, Dietz L, Naisbitt DJ, Park BK, Vocanson M, Nicolas JF, Keller M, Pichler WJ, Peiser M, Luch A, Wanner R, Maggi E, Cavani A, Rustemeyer T, Richter A, Thierse HJ, Sallusto F. 2010. T-cell recognition of chemical, protein allergens and drugs; toward the development of in vitro assays. Cell. Mol. Life Sci. 67: 4171-4184. ").<Reference> makeItLive());
link_effecttoeffect9.getReferenceIDs().add(new Reference(link_effecttoeffect9,dataSource,"4.	Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF 2009. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64: 1699-1714. ").<Reference> makeItLive());
link_effecttoeffect9.getReferenceIDs().add(new Reference(link_effecttoeffect9,dataSource,"5.	Api AM, Basketter DA, Cadby PA, Cano MF, Ellis G, Gerberick GF, Griem P, McNamee PM, Ryan CA and Safford B. 2008. Dermal sensitisation quantitative risk assessment (QRA) for fragrance ingredients. Reg. Toxicol. Pharmcol. 52: 3-23. ").<Reference> makeItLive());
link_effecttoeffect9.getReferenceIDs().add(new Reference(link_effecttoeffect9,dataSource,"6.	Zou T, Caton AJ, Koretzky GA, Kambayashi T. 2010. Dendritic cells induce regulatory T cell proliferation through antigen-dependent and –independent interactions. J. Immunol. 185:2790-2799. ").<Reference> makeItLive());

link_effecttoeffect11 = new Link_EffectToEffect(pathway, dataSource,effect_downstreameffect10, effect_adverseoutcome12);
link_effecttoeffect11.setLinkType(LinkType.DIRECT);link_effecttoeffect11.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect11,dataSource,"Definition","After recognition of a non-self peptide (i.e. foreign) presented by dendritic cells, T-cells are activated and form memory T-cell, which proliferate. If reactivated upon hapten presentation by skin dendritic cells, these memory T-cells will induce allergic contact dermatitis[1]). \n\nThis KER description is based only on the OECD document 2012 and needs updating. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
ReferenceIDW<Link_EffectToEffect> link_effecttoeffect11_weigth1= new ReferenceIDW<Link_EffectToEffect>(link_effecttoeffect11, dataSource, Link_EffectToEffect.class,3.0);
link_effecttoeffect11.getDescriptionIDs().set(new DescriptionSection_Structured(link_effecttoeffect11,dataSource,"(Key) Event Relationship Weight of Evidence","• Biological Plausibility:  \n\nIt is well known, recognised and experimentally proved that skin sensitisation is a T-cell mediated immune response. [1]  \n\n• Empirical Support for Linkage: \n\nUsing dinitrofluorobenzene and mice models, it was shown that cutaneous contact with reactive antigen induces KC/CXC chemokine ligand 1 production and neutrophil infiltration in an antigen, dose-dependent manner. The intensity of neutrophil infiltration into cutaneous antigen challenge sites, in turn, controls the number of antigen-primed T cells recruited into the site and the magnitude of immune response elicited[2]. \n\n• Uncertainties or Inconsistencies:\n\nNot disscussed in the AOP Wiki\n\n", link_effecttoeffect11_weigth1).setFormat(ContentFormat.TEXT).<DescriptionSection_Structured> makeItLive(), 1);
link_effecttoeffect11.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect11,dataSource,"Evidence Supporting Taxonomic Applicability","Not disscussed in the AOP Wiki").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 2);
link_effecttoeffect11.getDescriptionIDs().set(new DescriptionSection(link_effecttoeffect11,dataSource,"Quantitative Understading","Not disscussed in the AOP Wiki").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 3);
link_effecttoeffect11.getReferenceIDs().add(new Reference(link_effecttoeffect11,dataSource,"1.	Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. 2009. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64: 1699-1714. ").<Reference> makeItLive());
link_effecttoeffect11.getReferenceIDs().add(new Reference(link_effecttoeffect11,dataSource,"2.	Engeman T, Gorbachev AV, Kish DD, Fairchild RL. 2004. The intensity of neutrophil infiltration controls the number of antigen-primed CD8 T cells recruited into cutaneous antigen challenge sites. J. Leukocyte Biol. 76:941-949. ").<Reference> makeItLive());

testresponsemapping13 = new TestResponseMapping(pathway, dataSource, test_inchemico14, effect_downstreameffect6);

testresponsemapping15 = new TestResponseMapping(pathway, dataSource, test_invitro18, effect_downstreameffect7);

testresponsemapping16 = new TestResponseMapping(pathway, dataSource, test_invitro19, effect_downstreameffect7);

testresponsemapping17 = new TestResponseMapping(pathway, dataSource, test_invitro20, effect_downstreameffect7);

testresponsemapping22 = new TestResponseMapping(pathway, dataSource, test_inchemico23, effect_molecularinitiatingevent3);

testresponsemapping27 = new TestResponseMapping(pathway, dataSource, test_inchemico28, effect_molecularinitiatingevent3);

testresponsemapping29 = new TestResponseMapping(pathway, dataSource, test_inchemico30, effect_downstreameffect6);

testresponsemapping31 = new TestResponseMapping(pathway, dataSource, test_inchemico32, effect_downstreameffect6);

testresponsemapping33 = new TestResponseMapping(pathway, dataSource, test_inchemico34, effect_downstreameffect7);

testresponsemapping35 = new TestResponseMapping(pathway, dataSource, test_invivo36, effect_downstreameffect10);

testresponsemapping37 = new TestResponseMapping(pathway, dataSource, test_invivo38, effect_downstreameffect10);

testresponsemapping39 = new TestResponseMapping(pathway, dataSource, test_invivo40, effect_adverseoutcome12);

testresponsemapping41 = new TestResponseMapping(pathway, dataSource, test_invivo42, effect_adverseoutcome12);

pathway.updateEssentiality();
EssetialityDescription essentiality = pathway.getEssentiality();
DescriptionSection_Structured dss;
pathway.getDescriptionIDs().set(new DescriptionSection(pathway,dataSource,"Abstract","Skin sensitisation is a term used to denote the regulatory hazards known as human allergic contact dermatitis or rodent contact hypersensitivity, an important health endpoint taken into consideration in hazard and risk assessment of chemicals. Skin sensitisation is an immunological process that is described in two phases: the induction of sensitisation and the subsequent elicitation of the immune reaction. The first phase includes a sequential set of events which are described in this Adverse Outcome Pathway (AOP). The molecular initiating event (MIE) is covalent binding to skin proteins (specifically, to cysteine and/or lysine residues) which leads to keratinocytes' activation, a key event (KE) at cellular level. Another key event at cellular level is activation of dendritic cells, which is caused by hapten-protein complexes as well as by signalling from activated keratinocytes. Dendritic cells subsequently mature and migrate out of the epidermis to the local lymph node where they display major histocompatibility complex molecules, which include part of the hapten-protein complex to naive T-lymphocytes (T-cells). This induces differentiation and proliferation of allergen chemical-specific memory T-cells. This signifies the consecutive KE resulting in the acquisition of sensitisation, the adverse outcome on organ level. A sensitised subject has the capacity then to mount a more accelerated secondary response to the same chemical. Thus, if exposure occurs again, at the same or a different skin site, an aggressive immune response will be elicited resulting in allergic contact dermatitis. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 0);
pathway.getDescriptionIDs().set(new DescriptionSection(pathway,dataSource,"Quantitative Considerations","The final aspect of the OECD approach to using the AOP concept is an assessment of the quantitative understanding of an AOP. This includes the evaluation of the experimental data and models used to quantify the molecular initiating event and other key events. It also includes transparent determination of thresholds and response-to-response relationships used to scale in chemico and in vitro effects to in vivo outcomes. For skin sensitisation, a major hurdle is moving from a qualitative AOP to a quantitative AOP. While the assessment of the experimental evidence, empirical data and confidence in the AOP expressed by the Weight-of-Evidence clearly supports the qualitative AOP as a means to identify and characterize the potential for a chemical to be a sensitiser, these same assessments clearly reveal the current lack of ability to consistently predict relative potency. One aspect to be resolved is that of the in vivo data with which to scale the response-to-response ratios. Because the Local Lymph Node Assay (LLNA) can directly quantify the adverse outcome[42], public databases have recently been made available ([43];[44]). LLNA results are often compared with results from alternative methods (e.g.[33]). Such one-to-one comparisons may not be the best approach. As noted by Basketter et al.[42], the LLNA is not without limitations, including variability between EC3 values or any other value (i.e. ECx) within mechanistic classes with equal or near equal chemical reactivity. The specific nature of the in vivo relationship between irritation and sensitisation has yet to be elucidated. \n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 3);
pathway.getDescriptionIDs().set(new DescriptionSection(pathway,dataSource,"Applicability of the AOP","• Life Stage Applicability: \n\nThis proposed skin sensitisation AOP is neither sex-dependant nor associated with a certain life stage. \n\n• Taxonomic Applicability: \n\nmouse Mus musculus - Strong\n\nhuman Homo sapiens- Strong \n\nIn vivo testing focuses on mouse, guinea pig and men. \n\nThe molecular initating event of the present AOP is the hapten-protein binding. While covalent reactions with thiol groups and to lesser extent amino groups, are clearly supported by the proposed AOP, reactions targeting other nucleophiles may or may not be supported by the proposed AOP. Limited data on chemical reactivity shows that two competing reactions are possible, the faster reaction dominates. However, this has yet to be proven in vitro or in vivo. \n\n• Sex Applicability: Unspecific\n\n").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 4);
pathway.getDescriptionIDs().set(new DescriptionSection(pathway,dataSource,"Considerations for Potential Applications of the AOP (optional)","This AOP study[45] describing mechanistic knowledge has supported the development of a number of methods for assessing chemical sensitisation hazard potential or potency without the need for animal testing by measuring the impact of chemical sensitisers on the identified key events[46];[47]. This AOP also forms the mechanistic basis for the development of Integrated Approaches to Testing and Assessment (IATA)[48];[49]. Additionally, data-driven approaches for predicting sensitizer potency also have been developed[50];[51];[52]. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 5);
pathway.getDescriptionIDs().set(new DescriptionSection(pathway,dataSource," Overall Assessment of the AOP"," 1. Concordance of dose-response relationships \n\nWhile no specific citations were found, an examination of the experimental data for selected compounds (e.g. 1-chloro-2,4-dinitrobenzene) reveals general agreement among the dose-response relationships both within and between intermediate endpoints (see Annex 1[1]). With exceptions, there is agreement between sensitisers initiated by covalent binding to proteins and non-sensitisers tested in mice, guinea-pigs, and humans; this is especially the case for extreme and strong sensitisers but lesser so for weak and non-sensitisers. One problem is that earlier results, especially with the guinea-pig, were not dose response experiments. Chemical reactivity data show very good concordance of dose-response relationships regardless of the method. In general, available data from in vitro assays are fragmentary and often qualitative (i.e., yes/no). \n\n2. Temporal concordance among the key events and adverse effect; \n\nThere is good agreement between the sequences of biochemical and physiological events leading to skin sensitisation (see[2];[3];[4];[5];[6];[7]). \n\n3. Strength, consistency, and specificity of association of adverse effect and initiating event \n\nThere is excellent strength, as well as good consistency and high specificity, of the association between in vivo skin sensitisation and in chemico protein binding. This is especially true for reactions that have thiol as the preferred molecular target. Based on linear regression analyses, there is excellent interlaboratory/protocol correlations within and between nucleophile depletion and adduct formation methods[8]. \n\n4. Biological plausibility, coherence, and consistency of the experimental evidence \n\nThe in chemico, in vitro, and in vivo experimental evidence is logical and consistent with the mechanistic plausibility proposed by covalent reactions based on the protein binding theory ([2];[3];[7]). In selected cases, (e.g. 1-chloro-2,4-dinitrobenzene) where the same compound has been examined in a variety of assays (see Annex 1[1]), the coherence and consistency of the experimental data is excellent. \n\n5. Uncertainties, inconsistencies and data gaps. \n\nUncertainties include the structural and physicochemical cut-offs between theoretical and measured reactivity[8], the significance of the preferred amino acid target (e.g., cysteine versus lysine)[9], the significance of Th1 or type 1 (IFN-γ) versus Th2 or type 2 (IL-2, IL-4, IL-13) cytokine secretion profiles[10], and sensitisation measurements in different in vivo models. \n\nInconsistencies within the reported data are seen. There are differences between in vitro responses for highly similar chemicals (see[11];[12]). There are differences within and between in vivo test results for highly similar chemicals (see Annex C[13]). Highly hydrophobic chemicals, which are in vivo sensitisers, are not active in aquatic-based in chemico or in vitro assays. The specific nature of the relationship between irritation and sensitisation has yet to be elucidated. \n\nData gaps: Based on the more than 50 chemical reactions associated with covalent binding to thiol or primary amine moieties[9] in vitro data for keratinocytes, dendritic cells, and T-cell assays, as well as in vivo sensitisation data, is incomplete in that it does not cover the chemical spaces associated with many of these chemical reactions; in chemico data is also incomplete, especially for reactions that favour amino acid targets other than cysteine. ").setFormat(ContentFormat.TEXT).<DescriptionSection> makeItLive(), 6);
pathway.getDescriptionIDs().set(new DescriptionSection(pathway,dataSource," Weight of Evidence Summary Tables"," <table class=\"table\" border=\"1\">\n\n<tbody>\n\n<tr><th rowspan=\"2\">Support for Biological Plausibility of KERs</th><th>Defining Question</th><th>High (Strong)</th><th>Moderate</th><th>Low (Weak)</th></tr>\n\n<tr>\n\n<td>Is there a mechanistic relationship between KEup and KEdown consistent with established biological knowledge?</td>\n\n<td>Extensive understanding of the KER based on previous documentation and broad acceptance.</td>\n\n<td>KER is plausible based on analogy to,accepted biological relationships, but scientific understanding is incomplete.</td>\n\n<td>Empirical support for association between KEs, but the structural or functional relationship between them is not understood.</td>\n\n</tr>\n\n<tr>\n\n<td>MIE =&gt; KE1:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">It is well accepted and experimentally proved that upon hapten application, keratinocytes are activated and produce various chemical mediators (e.g. TNFa, IL-1&beta;, and prostaglandin E2) <sup id=\"cite_ref-Honda_2013_14-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Honda_2013-14\"><span style=\"font-size: small;\">[14]</span></a></sup>;<sup id=\"cite_ref-Erkes_2014_15-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Erkes_2014-15\"><span style=\"font-size: small;\">[15]</span></a></sup>.</td>\n\n</tr>\n\n<tr>\n\n<td>MIE =&gt; KE2:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">It is accepted and experimentally proved that during skin sensitisation process,immature epidermal and dermal dendritic cells recognize and internalize the hapten-protein complex formed during covalent binding and subsequently mature and migrate to the local lymph nodes. <sup id=\"cite_ref-Ryan_2005_16-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Ryan_2005-16\"><span style=\"font-size: small;\">[16]</span></a></sup>;<sup id=\"cite_ref-Ryan_2007_17-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Ryan_2007-17\"><span style=\"font-size: small;\">[17]</span></a></sup>;<sup id=\"cite_ref-Kimber_2011_18-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Kimber_2011-18\"><span style=\"font-size: small;\">[18]</span></a></sup>.</td>\n\n</tr>\n\n<tr>\n\n<td>KE1 =&gt; KE2:</td>\n\n<td>Moderate</td>\n\n<td colspan=\"3\">Keratinocyte response activates multiple events, including the release of pro-inflammatory cytokines (e.g. IL-18) and the induction of cyto-protective cellular pathways. Under the influence of fibroblast- blood endothelial- and lymph endothelial-chemokines (e.g. CCL19, CCL21) and epidermal cytokines (e.g. IL-1&alpha;, IL-1&beta;, IL-18, tumour necrosis factor alpha (TNF&alpha;)) maturing dendritic cells migrate from the epidermis to the dermis of the skin and then to the proximal lymph nodes. <sup id=\"cite_ref-Antonopoulos_2008_19-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Antonopoulos_2008-19\"><span style=\"font-size: small;\">[19]</span></a></sup>;<sup id=\"cite_ref-Ouwehand_2008_20-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Ouwehand_2008-20\"><span style=\"font-size: small;\">[20]</span></a></sup>.</td>\n\n</tr>\n\n<tr>\n\n<td>KE2 =&gt; KE3:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">It is well accepted and experimentally proved that in the local lymph node, maturedendritic cells present the hapten-protein complex to T-cells via a majorhistocompatibility complex molecule (MHC)<sup id=\"cite_ref-Ouwehand_2008_20-1\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Ouwehand_2008-20\"><span style=\"font-size: small;\">[20]</span></a></sup>;<sup id=\"cite_ref-Antonopoulos_2008_19-1\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Antonopoulos_2008-19\"><span style=\"font-size: small;\">[19]</span></a></sup>.\n\n<p>T-cells are typically affected by protein-hapten complexes presented by dendritic cells on MHC molecules. The T-cell will be then activated to form a memory T-cell, which subsequently proliferates<sup id=\"cite_ref-Vocanson_2009_4-1\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Vocanson_2009-4\"><span style=\"font-size: small;\">[4]</span></a></sup>.</p>\n\n</td>\n\n</tr>\n\n<tr>\n\n<td>KE3 =&gt; AO:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">It is well known, recognised and experimentally proved that skin sensitisation is a T-cell mediated immune response. <sup id=\"cite_ref-Vocanson_2009_4-2\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Vocanson_2009-4\"><span style=\"font-size: small;\">[4]</span></a></sup></td>\n\n</tr>\n\n<tr>\n\n<td>MIE =&gt; AO:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">Haptenation is widely accepted as molecular initiating event for skin sensitisation. In the form of a modified protein <sup id=\"cite_ref-Lepoittevin_2011_21-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Lepoittevin_2011-21\"><span style=\"font-size: small;\">[21]</span></a></sup>, the haptenation provides a source of antigen recognised by the immune system as non-self<sup id=\"cite_ref-Martin_1994_22-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Martin_1994-22\"><span style=\"font-size: small;\">[22]</span></a></sup>;<sup id=\"cite_ref-Weltzien_1996_23-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Weltzien_1996-23\"><span style=\"font-size: small;\">[23]</span></a></sup>;<sup id=\"cite_ref-MacKay_2013_24-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-MacKay_2013-24\"><span style=\"font-size: small;\">[24]</span></a></sup>.</td>\n\n</tr>\n\n</tbody>\n\n</table>\n\n<p>&nbsp;</p>\n\n<table class=\"table\" border=\"1\">\n\n<tbody>\n\n<tr><th rowspan=\"2\">Empirical Support for KERs</th><th>Defining Question</th><th>High (Strong)</th><th>Moderate</th><th>Low (Weak)</th></tr>\n\n<tr>\n\n<td>Does empirical evidence support that a change in KEup leads to an appropriate change in KEdown? Does KEup occur at lower doses, earlier time points, and higher in incidence than KEdown&nbsp;? Inconsistencies?</td>\n\n<td>Multiple studies showing dependent change in both events following exposure to a wide range of specific stressors. No or few critical data gaps or conflicting data.</td>\n\n<td>Demonstrated dependent change in both events following exposure to a small number of stressors. Some inconsistencies with expected pattern that can be explained by various factors.</td>\n\n<td>Limited or no studies reporting dependent change in both events following exposure to a specific stressor; and/or significant inconsistencies in empirical support across taxa and species</td>\n\n</tr>\n\n<tr>\n\n<td>MIE =&gt; KE1:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">Using a series of thiol-reactive cages fluorescent haptens (i.e. bromobimanes) deployed in combination with two photon fluorescence microscopy, immunohistochemistry, and proteomics, Simonson et al. (2011) identified the possible hapten targets in proteins in human skin. Key target found were the basal keratinocytes and the keratins K5 and K14<sup id=\"cite_ref-Simonsson_2011_25-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Simonsson_2011-25\"><span style=\"font-size: small;\">[25]</span></a></sup>.\n\n<p>In a review about murine contact sensitivity, Honda et al.<sup id=\"cite_ref-Honda_2013_14-1\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Honda_2013-14\"><span style=\"font-size: small;\">[14]</span></a></sup> reported that haptens can activate keratinocytes in an NLR-dependent manner. Among the NLR family, NLRP3 controls the production of proinflammatory cytokines through activation of caspase-1. Without NLRP3 or its adaptor protein ASC<sup id=\"cite_ref-Sutterwala_2006_26-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Sutterwala_2006-26\"><span style=\"font-size: small;\">[26]</span></a></sup>;<sup id=\"cite_ref-Watanabe_2007_27-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Watanabe_2007-27\"><span style=\"font-size: small;\">[27]</span></a></sup>;<sup id=\"cite_ref-Watanabe_2008_28-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Watanabe_2008-28\"><span style=\"font-size: small;\">[28]</span></a></sup>, the production of IL-1&beta; and IL-18 from keratinocytes was inhibited<sup id=\"cite_ref-Antonopoulos_2001_29-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Antonopoulos_2001-29\"><span style=\"font-size: small;\">[29]</span></a></sup>;<sup id=\"cite_ref-Nakae_2003_30-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Nakae_2003-30\"><span style=\"font-size: small;\">[30]</span></a></sup>;<sup id=\"cite_ref-Antonopoulos_2008_19-2\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Antonopoulos_2008-19\"><span style=\"font-size: small;\">[19]</span></a></sup>.</p>\n\n</td>\n\n</tr>\n\n<tr>\n\n<td>MIE =&gt; KE2:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">Using an flow-cytometric assay, the influence of contact sensitisers on endocytic mechanisms in murine Langerhans cells was measured. Epidermal cell suspensions were labelled with a monoclonal antibody directed to MHC class II molecules and pH-sensitive fluorochrome-coupled second step reagents. Study reported that stimulation with well-known sensitising compounds resulted in a partial conservation of the fluorescence intensity due to the internalisation of the labelled complexes into less acidic compartments. For untreated Langerhans cells or in the presence of irritants a significant quenching of fluorescence intensity due to the internalization of the MHC-antibody complexes into acidic compartments was noticed<sup id=\"cite_ref-Lempertz_1996_31-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Lempertz_1996-31\"><span style=\"font-size: small;\">[31]</span></a></sup>.\n\n<p>In the h-CLAT assay measuring the expression of CD86 and CD54 protein markers on the surface of the human monocytic leukemia cell line THP-1, the cell exposure to known non sensitisers does not increase cell biomarker expression. On the contrary, exposure to well-known sensitisers leads to an increase of the CD86 and CD54 expression<sup id=\"cite_ref-Sakaguchi_2009_32-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Sakaguchi_2009-32\"><span style=\"font-size: small;\">[32]</span></a></sup>;<sup id=\"cite_ref-Ashikaga_2010_33-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Ashikaga_2010-33\"><span style=\"font-size: small;\">[33]</span></a></sup>.</p>\n\n</td>\n\n</tr>\n\n<tr>\n\n<td>KE1 =&gt; KE2:</td>\n\n<td>Moderate</td>\n\n<td colspan=\"3\">Matjeka et al. (2012) exposed HaCaT cell line used as a model of human keratinocytes to skin sensitisers for one hour and then, after washed off, cocultured them with dendritic cells. Data showed that exposure of dendritic cells to chemically treated HaCaT cells led to the activation of dendritic cells measured by CD83 and CD86 upregulation<sup id=\"cite_ref-Matjeka_2012_34-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Matjeka_2012-34\"><span style=\"font-size: small;\">[34]</span></a></sup>.</td>\n\n</tr>\n\n<tr>\n\n<td>KE2 =&gt; KE3:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">A recent study showed in mice model that dendritic cells coordinate the interactions that are necessary to initiate polyclonal regulatory T cells proliferation<sup id=\"cite_ref-Zou_2010_35-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Zou_2010-35\"><span style=\"font-size: small;\">[35]</span></a></sup>.</td>\n\n</tr>\n\n<tr>\n\n<td>KE3 =&gt; AO:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">Using dinitrofluorobenzene and mice models, it was shown that cutaneous contact with reactive antigen induces KC/CXC chemokine ligand 1 production and neutrophil infiltration in an antigen, dose-dependent manner. The intensity of neutrophil infiltration into cutaneous antigen challenge sites, in turn, controls the number of antigen-primed T cells recruited into the site and the magnitude of immune response elicited<sup id=\"cite_ref-Engeman_2004_36-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Engeman_2004-36\"><span style=\"font-size: small;\">[36]</span></a></sup>.</td>\n\n</tr>\n\n</tbody>\n\n</table>").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 7);
pathway.getDescriptionIDs().set(new DescriptionSection(pathway,dataSource," Essentiality of the Key Events Summary Table"," Since the 1930’s, there has been growing evidence that the main potency-determining step in skin sensitisation of industrial organic compounds is the formation of a stable hapten-protein conjugate (see[2];[3];[37]). Consequently, the molecular initiating event leading to skin sensitisation is postulated in this AOP to be covalent binding of electrophilic chemical species with selected nucleophilic molecular sites of action in skin proteins ([2];[3]). Protein binding reactions are a means of identifying different chemical structures associated with skin sensitisation, which may or may not lead to different expressions in other key events along the AOP. \n\n<table class=\"table\" border=\"1\">\n\n<tbody>\n\n<tr><th rowspan=\"2\">Support for Essentiality of KEs</th><th>Defining Question</th><th>High (Strong)</th><th>Moderate</th><th>Low (Weak)</th></tr>\n\n<tr>\n\n<td>Are downstream KEs and/or the AO prevented if an upstream KE is blocked?</td>\n\n<td>Direct evidence from experimental studies illustrating essentiality for at least one of the important KEs.</td>\n\n<td>Indirect evidence that sufficient modification of an expected modulating factor attenuates or augments a KE.</td>\n\n<td>No or contradictory experimental evidence of the essentiality of any of the KEs.</td>\n\n</tr>\n\n<tr>\n\n<td>KE1: Keratinocytes activation</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">When production of IL-1&beta; and IL-18 from keratinocytes was inhibited, it resulted in impaired DC migration<sup id=\"cite_ref-Antonopoulos_2001_29-1\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Antonopoulos_2001-29\"><span style=\"font-size: small;\">[29]</span></a></sup>;<sup id=\"cite_ref-Nakae_2003_30-1\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Nakae_2003-30\"><span style=\"font-size: small;\">[30]</span></a></sup>;<sup id=\"cite_ref-Antonopoulos_2008_19-3\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Antonopoulos_2008-19\"><span style=\"font-size: small;\">[19]</span></a></sup>.</td>\n\n</tr>\n\n<tr>\n\n<td>KE2: Dendritic cells activation</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">A study performed in mice showed than when both Langerhans cells and Langerin+ dermal dendritic cells are depleted using DTR KI- mice (in which diphtheria toxin receptor is inserted into the Langerin locus) and subsequently administration of diphtheria toxin (allowing Langerin+ cells to be ablated), the contact hypersensitivity response is abrogated. In contrast, in the bacterial artificial chromosome (BAC)-transgenic mice (in which the diphtheria toxin subunit A (DTA) is cloned into the human Langerin locus, resulting in mice devoid of Langerhans cells) that lack only epidermal Langerhans cells but have normal number of dendritic cells, the contact hypersensitivity is unaffected<sup id=\"cite_ref-Christensen_2011_38-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Christensen_2011-38\"><span style=\"font-size: small;\">[38]</span></a></sup>.\n\n<p>Kim et al (2013) showed that exposition of murine dendritic cells to bisabolangelone (inhibitor of dendritic cell functions) attenuated the production of pro-inflammatory cytokines including IL-12, IL-1&beta;, and TNF-alpha, migration to macrophage inflammatory protein-3 beta, and all-T cell activating ability of dendritic cells<sup id=\"cite_ref-Kim_2013_39-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Kim_2013-39\"><span style=\"font-size: small;\">[39]</span></a></sup>.</p>\n\n</td>\n\n</tr>\n\n<tr>\n\n<td>KE3: T-cells, activation and proliferation:</td>\n\n<td>Strong</td>\n\n<td colspan=\"3\">The use of ACY-1215, an histone deacetylase, prevented the development of contact hypersensitivity in mice in vivo by modulating CD8 T-cell activation and functions<sup id=\"cite_ref-Tsuji_2015_40-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Tsuji_2015-40\"><span style=\"font-size: small;\">[40]</span></a></sup>.\n\n<p>Another study showed that trichomide A exerts immunosuppressive activity against activated T lymphocytes and in an in vivo experiment they demonstrated that trichlomide A significantly ameliorate picryl chloride (PCI)-induced contact hypersensitivity in mice<sup id=\"cite_ref-Wang_2012_41-0\" class=\"reference\"><a href=\"https://aopwiki.org/wiki/index.php/Aop:40#cite_note-Wang_2012-41\"><span style=\"font-size: small;\">[41]</span></a></sup>.</p>\n\n</td>\n\n</tr>\n\n</tbody>\n\n</table>").setFormat(ContentFormat.HTML).<DescriptionSection> makeItLive(), 8);
dss = essentiality.getEssentialityDescription(effect_molecularinitiatingevent3);
dss.setContent("Since the 1930’s, there has been growing evidence that the main potency-determining step in skin sensitisation of industrial organic compounds is the formation of a stable hapten-protein conjugate (see[2];[3];[37]). Consequently, the molecular initiating event leading to skin sensitisation is postulated in this AOP to be covalent binding of electrophilic chemical species with selected nucleophilic molecular sites of action in skin proteins ([2];[3]). Protein binding reactions are a means of identifying different chemical structures associated with skin sensitisation, which may or may not lead to different expressions in other key events along the AOP. ");
dss.setFormat(ContentFormat.TEXT);
((ReferenceIDW<Link_EffectToEffect>) dss.getStructuredContent()).setWeight(3.0);
dss = essentiality.getEssentialityDescription(effect_downstreameffect6);
dss.setContent("When production of IL-1β and IL-18 from keratinocytes was inhibited, it resulted in impaired DC migration[29];[30];[19]. ");
dss.setFormat(ContentFormat.TEXT);
((ReferenceIDW<Link_EffectToEffect>) dss.getStructuredContent()).setWeight(3.0);
dss = essentiality.getEssentialityDescription(effect_downstreameffect7);
dss.setContent("A study performed in mice showed than when both Langerhans cells and Langerin+ dermal dendritic cells are depleted using DTR KI- mice (in which diphtheria toxin receptor is inserted into the Langerin locus) and subsequently administration of diphtheria toxin (allowing Langerin+ cells to be ablated), the contact hypersensitivity response is abrogated. In contrast, in the bacterial artificial chromosome (BAC)-transgenic mice (in which the diphtheria toxin subunit A (DTA) is cloned into the human Langerin locus, resulting in mice devoid of Langerhans cells) that lack only epidermal Langerhans cells but have normal number of dendritic cells, the contact hypersensitivity is unaffected[38]. \n\nKim et al (2013) showed that exposition of murine dendritic cells to bisabolangelone (inhibitor of dendritic cell functions) attenuated the production of pro-inflammatory cytokines including IL-12, IL-1β, and TNF-alpha, migration to macrophage inflammatory protein-3 beta, and all-T cell activating ability of dendritic cells[39]. \n\n");
dss.setFormat(ContentFormat.TEXT);
((ReferenceIDW<Link_EffectToEffect>) dss.getStructuredContent()).setWeight(3.0);
dss = essentiality.getEssentialityDescription(effect_downstreameffect10);
dss.setContent("The use of ACY-1215, an histone deacetylase, prevented the development of contact hypersensitivity in mice in vivo by modulating CD8 T-cell activation and functions[40]. \n\nAnother study showed that trichomide A exerts immunosuppressive activity against activated T lymphocytes and in an in vivo experiment they demonstrated that trichlomide A significantly ameliorate picryl chloride (PCI)-induced contact hypersensitivity in mice[41]. \n\n");
dss.setFormat(ContentFormat.TEXT);
((ReferenceIDW<Link_EffectToEffect>) dss.getStructuredContent()).setWeight(3.0);
dss = essentiality.getEssentialityDescription(effect_adverseoutcome12);
dss.setContent("");
dss.setFormat(ContentFormat.TEXT);
((ReferenceIDW<Link_EffectToEffect>) dss.getStructuredContent()).setWeight(0.0);
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"1. OECD 2012. The Adverse Outcome Pathway for skin sensitisation initiated by covalent binding to proteins. Part 2: use of the AOP to develop chemical categories and integrated assessment and testing approaches. OECD Environment Directorate Joint Meeting of the Chemicals Committee and the Working Party on chemicals, pesticides and biotechnology. ENV/JM/MONO(2012)10/PART2. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"2. Gerberick F, Aleksic M, Basketter D, Casati S, Karlberg AT, Kern P, Kimber I, Lepoittevin JP, Natsch A, Ovigne JM, Rovida C, Sakaguchi H and Schultz T. 2008. Chemical reactivity measurement and the predictive identification of skin sensitisers. Altern. Lab. Anim.36: 215-242. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"3. Karlberg A-T, Bergström MA, Börje A, Luthman K and Nilsson JL. 2008. Allergic contact dermatitis- formation, structural requirements, and reactivity of skin sensitizers. Chem. Res. Toxicol. 21: 53-69. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"4. Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF 2009. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64: 1699-1714. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"5.Aeby P, Ashikaga T, Bessou-Touya S, Schapky A, Geberick F, Kern P, Marrec-Fairley M, Maxwell G, Ovigne JM, Sakaguchi H, Reisinger K, Tailhardat M, Martinozzi-Teisser S and Winkler P. 2010. Identifying and characterizing chemical skin sensitizers without animal testing; Colipa’s research and methods development program. Toxicol. In Vitro 24: 1465-1473. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"6. Basketter DA and Kimber I. 2010. Contact hypersensitivity. In: McQueen, C.A. (ed) Comparative Toxicology Vol. 5, 2nd Ed. Elsevier, Kidlington, UK, pp. 397-411. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"7. Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau A, Aptula A, Bal-Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E, Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Leite SB, Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tähti H, Testai E, van Delft J, van Loveren H, Vinken M, Worth A, Zaldivar JM. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.2011. Arch Toxicol.85(5):367-485. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"8. Schwöbel JAH, Koleva YK, Bajot F, Enoch SJ, Hewitt M, Madden JC, Roberts DW, Schultz TW and Cronin MTD. 2011. Measurement and estimation of electrophilic reactivity for predictive toxicology. Chem. Rev. 111: 2562-2596. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"9. OECD 2011. Report of the Expert Consultation on Scientific and Regulatory Evaluation of Organic Chemistry-based Structural Alerts for the Identification of Protein-binding Chemicals. OECD Environment, Health and Safety Publications Series on Testing and Assessment No. 139. ENV/JM/MONO(2011)9. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"10. Hopkins JE, Naisbitt DJ, Kitteringham NR, Dearman RJ, Kimber I, Park BK. 2005. Selective haptenation of cellular or extracellular proteins by chemical allergens: Association with cytokine polarization. Chem. Res. Toxicol. 18: 375-381. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"11.Natsch A and Emter R. 2008. Skin sensitizers induce antioxidant response element dependent genes: Application to the in vitro testing of the sensitisation potential of chemicals. Toxicol. Sci. 102: 110-119. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"12. McKim JM Jr, Keller DJ III, Gorski JR. 2010. A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan. Ocul. Toxicol. 29: 171-192. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"13. European Centre for Ecotoxicological and Toxicological Chemicals. 2010. High information content technologies in support of read-across in chemical risk assessment. Technical report No109. p87. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"14. Honda T, Egawa G, Grabbe S, Kabashima K. 2013. Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. J. Invest. Dermatol. 133: 303-315. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"15. Erkes DA, Selvan RS. 2014. Hapten-induced contact hypersensitivity, autoimmune reactions, and tumour regression: plausibility of mediating antitumor immunity. J. Immunol. Res. Article ID 175265 ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"16. Ryan CA, Gerberick GF, Gildea LA, Hulette BC, Bettis CJ, Cumberbatch M, Dearman RJ, Kimber I. 2005. Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment. Toxicol. Sci. 88: 4-11. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"17.Ryan CA, Kimber I, Basketter DA, Pallardy M, Gildea LA, Gerberick GF. 2007. Dendritic cells and skin sensitisation. Biological roles and uses in hazard identification. Toxicol. Appl. Pharmacol. 221: 384-394. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"18. Kimber I, Basketter DA, Gerberick GF, Ryan CA, Dearman RJ. 2011. Chemical allergy: Translating biology into hazard characterization. Toxicol. Sci. 120(S1): S238-S268 ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"19. Antonopoulos C, Cumberbatch M, Mee JB, Dearman RJ, Wei XQ, Liew FY, Kimber I, Groves RW. 2008. IL-18 is a key proximal mediator of contact hypersensitivity and allergen induced Langerhans cell migration in murine epidermis. J. Leukoc. Biol. 83: 361-367. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"20. Ouwehand K, Santegoets SJAM, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S. 2008. CXCL12 is essential for migration of activated Langerhans cells for epidermis to dermis. Eur. J. Immunol. 38: 3050-3059 ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"21. Lepoittevin JP, Basketter DA, Goossens A, et al. 2011. Allergic contact dermatitis: the molecular basis. Berlin, Germany: Springer. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"22. Martin S, Weltzien HU. 1994. T cell recognition of haptens, a molecular view. Int. Arch. Allergy Immunol. 104: 10-16. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"23. Weltzien HU, Moulon C, Martin S, et al. 1996. T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 107: 141-151. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"24. MacKay C, Davies M, Summerfield V, Maxwell G. 2013. From pathways to people: applying the adverse outcome pathway (AOP) for skin sensitization to risk assessment. ALTEX 30 (4/13):473-486 ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"25.Simonsson C, Andersson SI, Stenfeldt AL, Bergstrom J, Bauer B, Jonsson CA, Ericson MB, Broo KS. 2011. Caged fluorescent haptens reveal the generation of cryptic epitopes in allergic contact dermatitis. J.Invest. Immunol. 131: 1486-1493. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"26. Sutterwala FS, Ogura Y, Szczepanik M, et al. 2006. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24:317-327. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"27. Watanabe H, Gaide O, Petrilli V, et al. 2007. Activation of the IL-1beta-processing inflammasone is involved in contact hypersensitivity. J.Invest. Dermatol. 127:1956-1963. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"28. Watanabe H, Gehrke S, Contassot E, et al. 2008. Danger signalling through the inflammasone acts as a master switch between tolerance and sensitization. J. Immunol. 180:5826-5832. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"29. Antonopoulos C, Cumberbatch M, Dearman RJ, Daniel RJ, Kimber I, Groves RW. 2001. Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. J. Immunol. 166: 3672-3677. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"30. Nakae S, Komiyama Y, Narumi S, Sudo K, Horai R, Tagawa Y, Matsushima K, Asano M, Iwakura Y. 2003. IL-1-induced tumor necrosis factor- elicits inflammatory cell infiltration in the skin by inducing IFN-γ-inducible protein 10 in the elicitation phase of the contact hypersensitivity response. Int. Immunol. 15(2): 251-260. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"31. Lempertz U, Kühn U, Knop J and Becker D. 1996. An approach to predictive testing of contact sensitizers in vitro by monitoring their influence on endocytic mechanisms. Internat. Arch. Allergy Immunol. 111: 64-70. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"32. Sakaguchi H, Ashikaga T, Miyazawa M, Kosaka N, Ito Y, Yoneyama K, Sono S, Itagaki H, Toyoda H, Suzuki H. 2009. The relationship between CD86/CD54 expression and THP-1 cell viability in an in vitro skin sensitisation test-human cell line activation test (h-CLAT). Cell Biol. Toxicol. 25: 109-126. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"33. Ashikaga T, Sakaguchi H, Sono S, Kosaka N, Ishikawa M, Nukada Y, Miyazawa M, Ito Y, Nishiyama N, Itagaki H. 2010. A comparative evaluation of in vitro skin sensitisation tests: the human cell-line activation test (h-CLAT) versus the local lymph node assay (LLNA). Altern. Lab. Anim. 38:275-84. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"34. Matjeka T, Summerfield V, Noursadeghi M, Chain BM. 2012. Chemical toxicity to keratinocytes triggers dendritic cell activation via an IL-1 path. J. Allergy Clin. Immunol. Letters to the editor:247-205. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"35. Zou T, Caton AJ, Koretzky GA, Kambayashi T. 2010. Dendritic cells induce regulatory T cell proliferation through antigen-dependent and –independent interactions. J. Immunol. 185:2790-2799. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"36. Engeman T, Gorbachev AV, Kish DD, Fairchild RL. 2004. The intensity of neutrophil infiltration controls the number of antigen-primed CD8 T cells recruited into cutaneous antigen challenge sites. J. Leukocyte Biol. 76:941-949. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"37. Roberts DW, Aptula AO, Patlewicz G, Pease C. 2008. Chemical reactivity indices and mechanism-based read-across for non-animal based assessment of skin sensitisation potential. J. Appl. Toxicol. 28: 443-454. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"38. Christensen AD, Haase C. 2011. Immunological mechanisms of contact hypersensitivity in mice. APMIS 120: 1-27. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"39. Kim HS, Lee YJ, Lee HK, Kim JS, Park Y, Kang JS, Hwang BY, Hong JT, Kim Y, Han SB. 2013. Bisabolangelone inhibits dendritic cells functions by blocking MAPK and NF-ƙB signaling. Food Chem. Tox 59: 26-33. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"40. Tsuji G, Okiyama N, Villaroel VA, Katz S. 2015. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation. J. Allergy Clin. Immunol. 135(5): 1228-1239. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"41. Wang X, Zhang A, Gao J, Chen W, Wang S, Wu X, Shen Y, Ke Y, Hua Z, Tan R, Sun Y, Xu Q. 2014. Trichomide A, a natural cyclodepsipeptide, exerts immunosuppressive activity against activated T lymphocytes by upregulating SHP2 activation to overcome contact dermatitis. J. Invest. Dermatol. 134: 2737-2746. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"42. Basketter DA, McFadden JF, Gerberick F, Cochshott A, Kimber I. 2009. Nothing is perfect, not even the local lymph node assay: a commentary and the implications for REACH. Contact Dermatitis 60: 65-69. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"43. Gerberick GF, Ryan, CA, Kern, PS, Schlatter H, Dearman RJ, Kimber I, Patlewicz GY, Basketter DA. 2005. Compilation of historical lymph node data for evaluation of skin sensitisation alternative methods. Dermatitis 16: 157-202. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"44. Kern PS, Gerberick GF, Ryan CA, Kimber I, Aptula A, Basketter BA. 2010. Local lymph node data for the evaluation of skin sensitisation alternatives: A second compilation. Dermatitis 21: 8-32. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"45. MacKay C, Davies M, Summerfield V, Maxwell G. (2013). From pathways to people: applying the adverse outcome pathway (AOP) for skin sensitization to risk assessment. ALTEX.30(4):473-86. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"46. Adler S, Basketter D, Creton S, et al. 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects – 2010. Arch. Toxicol. 85, 367-485. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"47. Maxwell G, Aeby P, Ashikaga T, et al. 2011. Skin sensitisation: the Colipa strategy for developing and evaluating non-animal test methods for risk assessment. Altex 28, 50–55.  ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"48. Tollefsen KE, Scholz S, Cronin MT, Edwards SW, de Knecht J, Crofton K, Garcia-Reyero N, Hartung T, Worth A, Patlewicz G. 2014. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA). Regul. Toxicol. Pharmacol. 70(3):629-40. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"49. Bauch C, Kolle S N, Ramirez T, et al. 2012. Putting the parts together: combining in vitro methods to test for skin sensitizing potentials. Regul. Toxicol. Pharmacol. 63, 489-504. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"50. Jaworska J, Harol A, Kern PS, et al. 2011. Integrating non-animal test information into an adaptive testing strategy – skin sensitization proof of concept case. ALTEX 28, 211-225. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"51. Jaworska J, Dancik Y, Kern P, Gerberick F, Natsch A. 2013. Bayesian integrated testing strategy to assess skin sensitization potency: from theory to practice. J. Appl. Toxicol. 33(11):1353-64. ").<Reference> makeItLive());
pathway.getReferenceIDs().add(new Reference(pathway,dataSource,"52. Maxwell G, MacKay C, Cubberley R, Davies M, Gellatly N, Glavin S, Gouin T, Jacquoilleot S, Moore C, Pendlington R, Saib O, Sheffield D, Stark R, Summerfield V. 2014. Applying the skin sensitisation adverse outcome pathway (AOP) to quantitative risk assessment. Toxicol. In Vitro. 28(1):8-12. ").<Reference> makeItLive());
}
}
